

Efficacy and safety of rituximab in moderately to severely active systemic lupus erythematosus: The randomized, double-blind, phase 3 evaluation of rituximab trial

Arthritis and Rheumatism

62, 222-233

DOI: [10.1002/art.27233](https://doi.org/10.1002/art.27233)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Training and evaluation in SMEs: Manufacturing enterprises in the West Midlands. <i>Local Economy</i> , 1993, 8, 143-154.	0.8	14
2	Novel evidence-based systemic lupus erythematosus responder index. <i>Arthritis and Rheumatism</i> , 2009, 61, 1143-1151.	6.7	397
3	B Cell-Targeted Therapy in Lupus Nephritis: Game Not Over. <i>Nephrology Times</i> , 2010, 3, 1.	0.0	0
4	Biologics in the treatment of systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2010, 22, 504-509.	2.0	53
5	Perspectives on the management of late-onset systemic lupus erythematosus. <i>Aging Health</i> , 2010, 6, 475-480.	0.3	0
6	Targeting B cells to treat systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , 2010, 5, 627-636.	0.3	0
7	AmœœBœvalent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis. <i>Blood</i> , 2010, 116, 515-521.	0.6	60
8	B cells as therapeutic targets in SLE. <i>Nature Reviews Rheumatology</i> , 2010, 6, 326-337.	3.5	218
10	Pitfalls and Opportunities in Measuring Patient Outcomes in Lupus. <i>Current Rheumatology Reports</i> , 2010, 12, 229-236.	2.1	6
11	Advances in drug therapy for systemic lupus erythematosus. <i>BMC Medicine</i> , 2010, 8, 77.	2.3	37
12	Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: Two sides of the same coin. <i>Autoimmunity Reviews</i> , 2010, 9, 716-720.	2.5	29
13	The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2010, 10, 108-111.	2.5	33
14	Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2010, 62, 2443-2457.	6.7	90
15	Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry. <i>Arthritis and Rheumatism</i> , 2010, 62, 2458-2466.	6.7	352
16	Rituximab: Wanted dead or alive. <i>Arthritis and Rheumatism</i> , 2010, 62, 2188-2191.	6.7	14
17	Unanswered questions in evaluating rituximab efficacy: Comment on the article by Merrill et al. <i>Arthritis and Rheumatism</i> , 2010, 62, 2566-2566.	6.7	2
18	Bœœcell targeted therapies in human autoimmune diseases: an updated perspective. <i>Immunological Reviews</i> , 2010, 237, 264-283.	2.8	210
19	New and emerging treatment approaches to lupus. <i>Biologics: Targets and Therapy</i> , 2010, 4, 263.	3.0	19

#	ARTICLE	IF	CITATIONS
20	The Role of B Cells in Transplantation and Immunopathic Diseases. <i>Immune Network</i> , 2010, 10, 81.	1.6	1
21	Updates on the Treatment of Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 2028-2035.	3.0	152
22	The revised BILAG Index with numerical scoring in systemic lupus erythematosus: added value with some limitations. <i>Rheumatology</i> , 2010, 49, 1616-1617.	0.9	4
23	Lupus Nephritis. , 2010, , 308-321.		4
24	Immunotherapy of systemic sclerosis. <i>Immunotherapy</i> , 2010, 2, 863-878.	1.0	38
25	Contemporary treatment of systemic lupus erythematosus: an update for clinicians. <i>Therapeutic Advances in Chronic Disease</i> , 2010, 1, 163-175.	1.1	52
26	Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1603-1611.	0.5	121
27	Target Therapies in Systemic Lupus Erythematosus: Current State of the Art. <i>Mini-Reviews in Medicinal Chemistry</i> , 2010, 10, 956-965.	1.1	7
28	Targeting B cells with biologics in systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 1555-1561.	1.4	19
29	Successful treatment of autoimmune thrombocytopenic purpura with rituximab in a dialysis patient with systemic lupus erythematosus. <i>International Immunopharmacology</i> , 2010, 10, 632-634.	1.7	5
32	B Cell-Targeted Therapies for Systemic Lupus Erythematosus. <i>Drugs</i> , 2010, 70, 529-540.	4.9	58
34	Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: Past, present, and future. <i>Autoimmunity</i> , 2010, 43, 84-97.	1.2	75
35	Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1381-1394.	1.4	28
36	Mechanisms of B cell autoimmunity in SLE. <i>Arthritis Research and Therapy</i> , 2011, 13, 243.	1.6	225
37	Measuring outcomes in systemic lupus erythematosus clinical trials. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 455-468.	0.7	40
39	Neuropsychiatric Manifestations in Systemic Lupus Erythematosus. <i>CNS Drugs</i> , 2011, 25, 721-736.	2.7	59
40	Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2011, 365, 2110-2121.	13.9	2,265
41	Pediatric SLE"towards a comprehensive management plan. <i>Nature Reviews Rheumatology</i> , 2011, 7, 225-233.	3.5	61

#	ARTICLE	IF	CITATIONS
43	Terapia biológica dirigida contra los linfocitos B en el lupus eritematoso sistémico. Seminarios De La Fundaci3n Espaola De Reumatologaa, 2011, 12, 10-14.	0.1	0
44	Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus, 2011, 20, 709-716.	0.8	114
45	Shrinking lung syndrome: recognition, pathophysiology and therapeutic strategy. Expert Review of Respiratory Medicine, 2011, 5, 33-39.	1.0	32
46	Incidence of Infusion-Associated Reactions with Rituximab for Treating Multiple Sclerosis. Drug Safety, 2011, 34, 117-123.	1.4	26
47	Targeted therapies in systemic lupus erythematosus: successes, failures and future. Annals of the Rheumatic Diseases, 2011, 70, i64-i66.	0.5	29
48	Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus. Lupus, 2011, 20, 1219-1226.	0.8	49
49	Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrology Dialysis Transplantation, 2011, 26, 3987-3992.	0.4	61
50	The genetics of systemic lupus erythematosus and implications for targeted therapy. Annals of the Rheumatic Diseases, 2011, 70, i37-i43.	0.5	100
51	Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Research and Therapy, 2011, 13, R112.	1.6	53
52	Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Research and Therapy, 2011, 13, R75.	1.6	170
53	BAFF and selection of autoreactive B cells. Trends in Immunology, 2011, 32, 388-394.	2.9	141
54	Clinical research in systemic lupus erythematosus: immediate relevance to clinical practice. International Journal of Rheumatic Diseases, 2011, 14, 1-5.	0.9	9
55	Current and novel therapeutics in the treatment of systemic lupus erythematosus. Journal of Allergy and Clinical Immunology, 2011, 127, 303-312.	1.5	148
56	Belimumab for systemic lupus erythematosus. Lancet, The, 2011, 377, 2080.	6.3	8
57	B-Lymphocyte Biology in SLE. , 2011, , 143-161.		2
58	Contribution of dendritic cell/T cell interactions to triggering and maintaining autoimmunity. Biological Research, 2011, 44, 53-61.	1.5	9
60	Clearing the complexity: immune complexes and their treatment in lupus nephritis. International Journal of Nephrology and Renovascular Disease, 2011, 4, 17.	0.8	22
61	Rituximab in the Treatment of Bullous Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2011, 17, 142-144.	0.5	39

#	ARTICLE	IF	CITATIONS
62	Dr. Perl replies. <i>Journal of Rheumatology</i> , 2011, 38, 1217-1217.	1.0	1
63	Genetic and Pharmacological Modulation of Dendritic Cell-T Cell Interactions as a Therapeutic Strategy for Systemic Lupus Erythematosus. <i>Current Gene Therapy</i> , 2011, 11, 544-553.	0.9	7
64	Treatment of systemic lupus erythematosus with epratuzumab. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 175-182.	1.1	54
65	Challenges in the pursuit of immune tolerance. <i>Immunological Reviews</i> , 2011, 241, 49-62.	2.8	23
66	Rituximab Therapy in Refractory Neuropsychiatric Lupus: Current Clinical Evidence. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 364-372.	1.6	80
67	Novel Therapeutic Approaches to Lupus Glomerulonephritis: Translating Animal Models to Clinical Practice. <i>American Journal of Kidney Diseases</i> , 2011, 57, 498-507.	2.1	14
68	Emerging biological drugs: A new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events. <i>Autoimmunity Reviews</i> , 2011, 11, 56-60.	2.5	51
69	An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 54-59.	0.5	86
70	B cell depletion for autoimmune diseases in paediatric patients. <i>Clinical Rheumatology</i> , 2011, 30, 87-97.	1.0	44
71	Normalization of serum-free light chains in patients with systemic lupus erythematosus upon rituximab treatment and correlation with biological disease activity. <i>Clinical Rheumatology</i> , 2011, 30, 685-689.	1.0	27
72	Rituximab in the treatment of severe lupus myelopathy. <i>Clinical Rheumatology</i> , 2011, 30, 981-986.	1.0	29
73	Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians. <i>Clinical and Experimental Nephrology</i> , 2011, 15, 321-330.	0.7	17
74	Juvenile systemic lupus erythematosus: Review of clinical features and management. <i>Indian Pediatrics</i> , 2011, 48, 879-887.	0.2	22
76	Clinical Assessment and Management of Cytopenias in Lupus Patients. <i>Current Rheumatology Reports</i> , 2011, 13, 291-299.	2.1	33
77	Treatment of Mild, Moderate, and Severe Lupus Erythematosus: Focus on New Therapies. <i>Current Rheumatology Reports</i> , 2011, 13, 308-316.	2.1	24
78	Treatment of Lupus: Impact on Quality of Life. <i>Current Rheumatology Reports</i> , 2011, 13, 324-337.	2.1	7
79	Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. <i>American Journal of Hematology</i> , 2011, 86, 278-291.	2.0	21
80	Plasma cells in systemic lupus erythematosus: The long and short of it all. <i>European Journal of Immunology</i> , 2011, 41, 588-591.	1.6	41

#	ARTICLE	IF	CITATIONS
81	New and emerging treatments for lupus nephritis. <i>Dialysis and Transplantation</i> , 2011, 40, 67-71.	0.2	0
82	Current drugs in systemic lupus erythematosus. <i>Drug Development Research</i> , 2011, 72, 561-572.	1.4	1
83	Beyond transitional selection: New roles for BLYS in peripheral tolerance. <i>Drug Development Research</i> , 2011, 72, 779-787.	1.4	13
84	Inhibition of the catalytic function of activation-induced cytidine deaminase promotes apoptosis of germinal center B cells in BXD2 mice. <i>Arthritis and Rheumatism</i> , 2011, 63, 2038-2048.	6.7	29
85	B cell biomarkers of rituximab responses in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011, 63, 3038-3047.	6.7	191
86	Research Highlights. <i>Immunotherapy</i> , 2011, 3, 1293-1295.	1.0	2
88	Emerging small molecule and biological therapeutic approaches for the treatment of autoimmunity. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 23-39.	1.9	5
89	Immunoadsorption (IAS) for systemic lupus erythematosus. <i>Lupus</i> , 2011, 20, 115-119.	0.8	19
90	Systemic lupus erythematosus - an update. <i>Drug and Therapeutics Bulletin</i> , 2011, 49, 81-84.	0.3	5
91	<i>Geriatric Rheumatology</i> . , 2011, , .		6
92	Neuropsychiatric Manifestations of Rheumatic Diseases in the Elderly. , 2011, , 27-34.		0
93	Immunologic Reconstitution After Rituximab in Systemic Lupus Erythematosus: Why Should We Care?. <i>Journal of Rheumatology</i> , 2011, 38, 587-589.	1.0	3
94	An Acquired Defect in IgG-Dependent Phagocytosis Explains the Impairment in Antibody-Mediated Cellular Depletion in Lupus. <i>Journal of Immunology</i> , 2011, 187, 3888-3894.	0.4	33
95	Murine Models of Systemic Lupus Erythematosus. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-19.	3.0	306
97	Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis. <i>Rheumatology</i> , 2011, 50, 1148-1152.	0.9	18
98	Pure red cell aplasia in a patient with lupus-like disease and thymoma. <i>Grand Rounds</i> , 2011, 11, 37-40.	0.2	1
99	Targeting the BLYS family in autoimmunity: a tale of mouse and man. <i>Clinical Investigation</i> , 2011, 1, 951-967.	0.0	5
100	Mycophenolate mofetil for the induction and maintenance treatment of lupus nephritis. <i>Immunotherapy</i> , 2011, 3, 1431-1440.	1.0	1

#	ARTICLE	IF	CITATIONS
101	Glomerular diseases and transplantation: similarities in pathogenetic mechanisms and treatment options. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 35-41.	0.4	10
102	Antibody-Mediated Coengagement of Fc γ RIIb and B Cell Receptor Complex Suppresses Humoral Immunity in Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2011, 186, 4223-4233.	0.4	142
103	Validation of the Functional Assessment of Chronic Illness Therapy-Fatigue Scale in Patients with Moderately to Severely Active Systemic Lupus Erythematosus, Participating in a Clinical Trial. <i>Journal of Rheumatology</i> , 2011, 38, 672-679.	1.0	108
104	Therapeutic Targeting of B Cells for Rheumatic Autoimmune Diseases. <i>Pharmacological Reviews</i> , 2011, 63, 127-156.	7.1	95
105	Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 437-451.	1.3	3
106	Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1153-1159.	0.5	50
107	Are autoantibodies the targets of B-cell-directed therapy?. <i>Nature Reviews Rheumatology</i> , 2011, 7, 551-556.	3.5	22
108	Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. <i>Rheumatology</i> , 2011, 50, 222-229.	0.9	159
109	The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. <i>Rheumatology</i> , 2011, 50, 1401-1408.	0.9	81
110	Belimumab: First targeted biological treatment for systemic lupus erythematosus. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2011, 2, 317-319.	0.2	53
111	Belimumab in systemic lupus erythematosus: an update for clinicians. <i>Therapeutic Advances in Chronic Disease</i> , 2012, 3, 11-23.	1.1	10
112	Double Allogenic Mesenchymal Stem Cells Transplantations Could Not Enhance Therapeutic Effect Compared with Single Transplantation in Systemic Lupus Erythematosus. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-7.	3.3	40
113	Multicenter Retrospective Analysis of the Effectiveness and Safety of Rituximab in Korean Patients with Refractory Systemic Lupus Erythematosus. <i>Autoimmune Diseases</i> , 2012, 2012, 1-6.	2.7	18
114	Biological Therapy in Systemic Lupus Erythematosus. <i>International Journal of Rheumatology</i> , 2012, 2012, 1-9.	0.9	31
115	Concomitant cyclophosphamide and oral immunosuppressants with rituximab for systemic lupus erythematosus. <i>Rheumatology</i> , 2012, 51, 1131-1132.	0.9	6
116	Biologics for the treatment of systemic lupus erythematosus?. <i>Annals of Medicine</i> , 2012, 44, 225-232.	1.5	2
117	Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research. <i>Current Pharmaceutical Design</i> , 2012, 18, 1543-1555.	0.9	57
118	Lupus arthritis--do we have a clinically useful classification?. <i>Rheumatology</i> , 2012, 51, 771-779.	0.9	76

#	ARTICLE	IF	CITATIONS
119	Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. <i>Lupus</i> , 2012, 21, 1063-1076.	0.8	98
121	Lupus nephritis: prolonged immunoadsorption (IAS) reduces proteinuria and stabilizes global disease activity. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 618-626.	0.4	39
122	Rituximab in immunologic glomerular diseases. <i>MAbs</i> , 2012, 4, 198-207.	2.6	11
123	New and future therapies for lupus nephritis. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, 134-140.	0.6	12
124	Animal Models of Molecular Pathology. <i>Progress in Molecular Biology and Translational Science</i> , 2012, 105, 321-370.	0.9	40
125	Genetic susceptibility to lupus: the biological basis of genetic risk found in B cell signaling pathways. <i>Journal of Leukocyte Biology</i> , 2012, 92, 577-591.	1.5	66
126	B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab. <i>Biologics: Targets and Therapy</i> , 2012, 6, 347.	3.0	7
127	Systemic Lupus Erythematosus. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-2.	3.3	16
128	Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus. <i>International Journal of Rheumatology</i> , 2012, 2012, 1-11.	0.9	44
129	Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. <i>Rheumatology</i> , 2012, 51, 476-481.	0.9	68
130	Lupus nephritis. How latest insights into its pathogenesis promote novel therapies. <i>Current Opinion in Rheumatology</i> , 2012, 24, 457-465.	2.0	21
132	Rituximab Therapy and Autoimmune Disease. <i>Current Immunology Reviews</i> , 2012, 8, 94-100.	1.2	2
133	Anti Citrullinated Protein Antibodies and Mechanism of Action of Common Disease Modifying Drugs - Insights in Pathomechanisms of Autoimmunity. <i>Current Pharmaceutical Design</i> , 2012, 18, 4526-4536.	0.9	3
134	Targeting B cells in severe thrombotic thrombocytopenic purpura—a road to cure?*. <i>Critical Care Medicine</i> , 2012, 40, 317-318.	0.4	5
135	Treatment options for lupus nephritis: what lessons have we learned from the LUNAR study?. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 465-467.	0.3	0
136	The pathogenesis of systemic lupus erythematosus—an update. <i>Current Opinion in Immunology</i> , 2012, 24, 651-657.	2.4	258
138	Taming lupus—a new understanding of pathogenesis is leading to clinical advances. <i>Nature Medicine</i> , 2012, 18, 871-882.	15.2	390
139	Systemic Lupus Erythematosus in Children and Adolescents. <i>Pediatric Clinics of North America</i> , 2012, 59, 345-364.	0.9	214

#	ARTICLE	IF	CITATIONS
140	Rituximab: emerging treatment strategies of immune-mediated glomerular disease. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 413-421.	1.3	10
141	The Treatment of Lupus: General Principles. , 2012, , 53-66.		0
142	Role of type I interferons in the activation of autoreactive B cells. <i>Immunology and Cell Biology</i> , 2012, 90, 498-504.	1.0	182
143	American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. <i>Arthritis Care and Research</i> , 2012, 64, 797-808.	1.5	1,119
145	Rituximab—“it was the best of times, it was the worst of times. <i>Autoimmunity Reviews</i> , 2012, 11, 790-791.	2.5	17
146	B-cell targeted treatments for lupus: The journey counts as much as the destination. <i>Joint Bone Spine</i> , 2012, 79, 437-440.	0.8	1
147	Comparative Safety of Therapies in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 795-807.	0.8	1
148	Accelerated atherosclerosis in systemic lupus erythematosus: mechanisms and prevention approaches. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 527-539.	0.3	18
149	Belimumab for the management of systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 957-963.	1.4	6
151	Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients. <i>Arthritis Research and Therapy</i> , 2012, 14, 202.	1.6	28
152	Treatment targets in systemic lupus erythematosus: biology and clinical perspective. <i>Arthritis Research and Therapy</i> , 2012, 14, S3.	1.6	20
153	Unmet medical needs in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2012, 14, S4.	1.6	127
154	Synthetic lethality for linking the mycophenolate mofetil mode of action with molecular disease and drug profiles. <i>Molecular BioSystems</i> , 2012, 8, 3197.	2.9	4
155	Optimization of current and future therapy for autoimmune diseases. <i>Nature Medicine</i> , 2012, 18, 59-65.	15.2	79
156	The BILAG-2004 systems tally—a novel way of representing the BILAG-2004 index scores longitudinally. <i>Rheumatology</i> , 2012, 51, 2099-2105.	0.9	13
157	The discovery and development of belimumab: the anti-BLyS—“lupus connection. <i>Nature Biotechnology</i> , 2012, 30, 69-77.	9.4	137
158	B-cell-depleting Therapy in Systemic Lupus Erythematosus. <i>American Journal of Medicine</i> , 2012, 125, 327-336.	0.6	66
159	Recent Progress in the Treatment of Proliferative Lupus Nephritis. <i>American Journal of Medicine</i> , 2012, 125, 642-648.	0.6	6

#	ARTICLE	IF	CITATIONS
160	Lupus: Novel therapies in clinical development. <i>European Journal of Internal Medicine</i> , 2012, 23, 212-218.	1.0	21
163	Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?. <i>Annals of the New York Academy of Sciences</i> , 2012, 1274, 48-59.	1.8	34
164	New Therapeutic Targets in Systemic Lupus. <i>Reumatología Clínica (English Edition)</i> , 2012, 8, 201-207.	0.2	5
166	Cellular Targeting in Autoimmunity. <i>Current Allergy and Asthma Reports</i> , 2012, 12, 495-510.	2.4	11
167	Nuevas dianas terapéuticas en el lupus sistémico (parte 1/2). <i>Reumatología Clínica</i> , 2012, 8, 201-207.	0.2	10
168	Late-Onset Systemic Lupus Erythematosus. <i>Drugs and Aging</i> , 2012, 29, 181-189.	1.3	78
169	Current state of evidence on "off-label" therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland – a consensus report. <i>Lupus</i> , 2012, 21, 386-401.	0.8	71
170	Manage the neuropsychiatric manifestations of systemic lupus erythematosus with mostly empirical treatments. <i>Drugs and Therapy Perspectives</i> , 2012, 28, 11-14.	0.3	0
171	Shrinking Lung Syndrome Successfully Treated with Rituximab and Cyclophosphamide. <i>Respiration</i> , 2012, 84, 144-149.	1.2	40
172	Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus. <i>Arthritis Research and Therapy</i> , 2012, 14, R243.	1.6	87
173	APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis. <i>Arthritis Research and Therapy</i> , 2012, 14, R252.	1.6	57
174	B Cell Targeted Therapy in Rheumatic Disease. <i>Journal of Rheumatic Diseases</i> , 2012, 19, 67.	0.4	0
175	New treatment options for lupus – a focus on belimumab. <i>Therapeutics and Clinical Risk Management</i> , 2012, 8, 33.	0.9	17
176	Update on the Management of Systemic Lupus Erythematosus from a Pediatric Nephrology Perspective. <i>Current Rheumatology Reviews</i> , 2012, 8, 30-38.	0.4	0
177	Novel Pharmacologic Therapies in the Treatment of Systemic Lupus Erythematosus. <i>Hanyang Medical Reviews</i> , 2012, 32, 83.	0.4	0
178	Treatment of systemic lupus erythematosus. Part II. The role of biologic agents. <i>Reumatologia</i> , 2012, 6, 515-521.	0.5	0
179	Preclinical studies with synthetic peptides in systemic lupus erythematosus. <i>Frontiers in Bioscience - Landmark</i> , 2012, 17, 1940.	3.0	7
180	Update on the role of rituximab in kidney diseases and transplant. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 223-233.	1.4	15

#	ARTICLE	IF	CITATIONS
181	Role of autophagy in immunity and autoimmunity, with a special focus on systemic lupus erythematosus. <i>FASEB Journal</i> , 2012, 26, 1400-1412.	0.2	137
182	BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus. <i>Immunology and Cell Biology</i> , 2012, 90, 293-303.	1.0	79
183	Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study. <i>Arthritis and Rheumatism</i> , 2012, 64, 1215-1226.	6.7	1,083
184	The Rationale for BAFF Inhibition in Systemic Lupus Erythematosus. <i>Current Rheumatology Reports</i> , 2012, 14, 295-302.	2.1	31
185	New developments in the treatment of systemic lupus erythematosus. <i>Pediatric Nephrology</i> , 2012, 27, 727-732.	0.9	15
186	Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies. <i>Clinical and Experimental Immunology</i> , 2011, 167, 7-14.	1.1	42
187	Treatment of systemic lupus erythematosus: new advances in targeted therapy. <i>Annals of the New York Academy of Sciences</i> , 2012, 1247, 138-152.	1.8	38
188	How to treat refractory arthritis in lupus?. <i>Joint Bone Spine</i> , 2012, 79, 347-350.	0.8	8
189	The Systemic Lupus Erythematosus Responder Index (SRI); A new SLE disease activity assessment. <i>Autoimmunity Reviews</i> , 2012, 11, 326-329.	2.5	86
190	Rituximab â€” Shadow, illusion or light?. <i>Autoimmunity Reviews</i> , 2012, 11, 563-567.	2.5	19
192	Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. <i>Arthritis and Rheumatism</i> , 2012, 64, 493-503.	6.7	219
194	Retinal vasculitis in two pediatric patients with systemic lupus erythematosus: a case report. <i>Pediatric Rheumatology</i> , 2013, 11, 25.	0.9	27
195	Available evidence and outcome of off-label use of rituximab in clinical practice. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1689-1699.	0.8	16
196	Aberrant B Cell Selection and Activation in Systemic Lupus Erythematosus. <i>International Reviews of Immunology</i> , 2013, 32, 445-470.	1.5	28
197	Novel therapeutic agents in clinical development for systemic lupus erythematosus. <i>BMC Medicine</i> , 2013, 11, 120.	2.3	15
198	Renal involvement in autoimmune connective tissue diseases. <i>BMC Medicine</i> , 2013, 11, 95.	2.3	100
199	Biologic therapy for autoimmune diseases: an update. <i>BMC Medicine</i> , 2013, 11, 88.	2.3	202
200	Top 10 Developments in Lupus Nephritis. <i>Current Rheumatology Reports</i> , 2013, 15, 358.	2.1	4

#	ARTICLE	IF	CITATIONS
201	Indications for use and safety of rituximab in childhood renal diseases. <i>Pediatric Nephrology</i> , 2013, 28, 1001-1009.	0.9	11
202	B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 761-772.	1.3	10
203	Immunopathogenic mechanisms of systemic autoimmune disease. <i>Lancet, The</i> , 2013, 382, 819-831.	6.3	446
206	Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab. <i>Autoimmunity Reviews</i> , 2013, 12, 1085-1090.	2.5	211
207	Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. <i>Lancet, The</i> , 2013, 382, 809-818.	6.3	103
208	Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en el lupus eritematoso sistémico. <i>Reumatología Clínica</i> , 2013, 9, 281-296.	0.2	31
209	Lymphocyte transformation and autoimmune disorders. <i>Autoimmunity Reviews</i> , 2013, 12, 802-813.	2.5	26
210	Systemic Lupus Erythematosus: A Review of the Disease and Treatment Options. <i>The Consultant Pharmacist</i> , 2013, 28, 110-121.	0.4	92
211	Latest advances in connective tissue disorders. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2013, 5, 234-249.	1.2	10
212	Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. <i>Lupus</i> , 2013, 22, 1489-1503.	0.8	91
213	Current management of lupus nephritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 319-328.	1.4	34
214	Biologics in SLE: Towards new approaches. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 341-349.	1.4	23
215	Fatigue, health-related quality of life and other patient-reported outcomes in systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 363-375.	1.4	150
216	Targeted therapies in systemic lupus erythematosus. <i>Lupus</i> , 2013, 22, 978-986.	0.8	12
217	The role of B lymphocyte stimulator in B cell biology: implications for the treatment of lupus. <i>Lupus</i> , 2013, 22, 350-360.	0.8	19
218	Rituximab treatment in lupus nephritis – where do we stand?. <i>Lupus</i> , 2013, 22, 381-389.	0.8	31
219	SER Consensus Statement on the Use of Biologic Therapy for Systemic Lupus Erythematosus. <i>Reumatología Clínica (English Edition)</i> , 2013, 9, 281-296.	0.2	10
220	Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature. <i>Lupus</i> , 2013, 22, 664-674.	0.8	35

#	ARTICLE	IF	CITATIONS
221	Reprint of: B cell elimination in systemic lupus erythematosus. <i>Clinical Immunology</i> , 2013, 148, 344-358.	1.4	2
222	Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. <i>Lupus</i> , 2013, 22, 574-582.	0.8	76
223	Recent progress in conventional and biologic therapy for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii66-ii68.	0.5	8
224	Top 10 Recent Developments in Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus. <i>Current Rheumatology Reports</i> , 2013, 15, 380.	2.1	38
225	Is there an effective treatment for late-onset systemic lupus erythematosus?. <i>Aging Health</i> , 2013, 9, 437-450.	0.3	0
226	Future prospects in biologic therapy for systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2013, 9, 705-720.	3.5	48
227	Systemic lupus erythematosus: an update on current pharmacotherapy and future directions. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 723-737.	1.4	23
228	B-cell targeted therapeutics in clinical development. <i>Arthritis Research and Therapy</i> , 2013, 15, S4.	1.6	92
229	B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. <i>Arthritis Research and Therapy</i> , 2013, 15, S2.	1.6	109
230	Update on differences between childhood-onset and adult-onset systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2013, 15, 218.	1.6	112
231	The treatment of systemic lupus proliferative nephritis. <i>Pediatric Nephrology</i> , 2013, 28, 2069-2078.	0.9	7
232	Lupus Nephritis: Treatment of Resistant Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 154-161.	2.2	24
233	Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. <i>Autoimmunity Reviews</i> , 2013, 12, 854-859.	2.5	34
234	Autoantibodies. , 2013, , 273-285.		0
235	Eficacia y tolerabilidad de rituximab en el tratamiento de pacientes con rhusus. <i>ReumatologÃa ClÃnica</i> , 2013, 9, 201-205.	0.2	19
237	B-Cell Targeted Therapy With Rituximab for Thyroid Eye Disease: Closer to the Clinic. <i>Survey of Ophthalmology</i> , 2013, 58, 252-265.	1.7	21
238	Novel diagnostic approaches and costâ€“benefit balance of treatment of immune-mediated and rare disease in the era of biologic drugs: Lessons from the 15th Turin Congress on Immune Pathology and Orphan Disease. <i>Autoimmunity Reviews</i> , 2013, 12, 793-795.	2.5	5
239	Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus â€“ report of 17 cases and review of the literature. <i>Lupus</i> , 2013, 22, 932-939.	0.8	52

#	ARTICLE	IF	CITATIONS
240	Efficacy and Tolerability of Rituximab in Patients With Rhupus. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2013, 9, 201-205.	0.2	5
241	Lupus sistĀmico y dermatomiositis infantil. <i>EMC Pediatria</i> , 2013, 48, 1-13.	0.0	0
242	B-cell-targeted therapies in systemic lupus erythematosus. <i>Cellular and Molecular Immunology</i> , 2013, 10, 133-142.	4.8	65
243	Belimumab Therapy in Systemic Lupus Erythematosus. <i>BioDrugs</i> , 2013, 27, 225-235.	2.2	8
244	Rituximab biosimilars. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1049-1062.	1.4	34
245	B cell elimination in systemic lupus erythematosus. <i>Clinical Immunology</i> , 2013, 146, 90-103.	1.4	37
247	Targeting the complement system in systemic lupus erythematosus and other diseases. <i>Clinical Immunology</i> , 2013, 148, 313-321.	1.4	87
248	Efficacy and Safety of Nonbiologic Immunosuppressants in the Treatment of Nonrenal Systemic Lupus Erythematosus: A Systematic Review. <i>Arthritis Care and Research</i> , 2013, 65, 1775-1785.	1.5	50
249	Ten Developments in the Use of Biologicals for Systemic Lupus Erythematosus. <i>Current Rheumatology Reports</i> , 2013, 15, 337.	2.1	1
250	Subacute cutaneous lupus erythematosus in the course of rheumatoid arthritis: a relationship with TNF-Ā antagonists and rituximab therapy?. <i>Immunopharmacology and Immunotoxicology</i> , 2013, 35, 443-446.	1.1	9
251	B-Cell Targeted Therapies in Systemic Lupus Erythematosus. <i>BioDrugs</i> , 2013, 27, 85-95.	2.2	37
252	Human BĀ1 cells take the stage. <i>Annals of the New York Academy of Sciences</i> , 2013, 1285, 97-114.	1.8	141
253	Novel Therapies for SLE. , 2013, , 640-647.		0
254	New biologic therapy for systemic lupus erythematosus. <i>Current Opinion in Pharmacology</i> , 2013, 13, 405-412.	1.7	24
255	Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis. <i>BMJ Open</i> , 2013, 3, e002852.	0.8	19
256	The Pathogenesis of Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1357-1366.	3.0	351
257	Race and the response to therapies for lupus: how strong is the evidence?. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 471-481.	0.3	6
259	Ā%aluation thĀrapeutique dans le lupus ĀrythĀmateux systĀmique. , 2013, , 209-223.		0

#	ARTICLE	IF	CITATIONS
260	Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. <i>Rheumatology</i> , 2013, 52, 1313-1322.	0.9	115
261	Development of Systemic Lupus Erythematosus in NZM 2328 Mice in the Absence of any Single BAFF Receptor. <i>Arthritis and Rheumatism</i> , 2013, 65, 1043-1054.	6.7	35
262	Challenges and opportunities in SLE clinical trials. <i>Current Opinion in Rheumatology</i> , 2013, 25, 606-615.	2.0	11
263	Update on the treatment of lupus nephritis. <i>Current Opinion in Nephrology and Hypertension</i> , 2013, 22, 224-230.	1.0	26
264	New therapeutics in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2013, 25, 297-303.	2.0	22
265	Preliminary analysis of mortality associated with rituximab use in autoimmune diseases. <i>Autoimmunity</i> , 2013, 46, 487-496.	1.2	18
266	Towards treating lupus nephritis without oral steroids: a dream-come-true?. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1271-1272.	0.5	6
268	Prospective data collection of off-label use of rituximab in Australian public hospitals. <i>Internal Medicine Journal</i> , 2013, 43, 863-870.	0.5	18
269	Belimumab: targeted therapy for lupus. <i>International Journal of Rheumatic Diseases</i> , 2013, 16, 4-13.	0.9	11
270	B cell biology: implications for treatment of systemic lupus erythematosus. <i>Lupus</i> , 2013, 22, 342-349.	0.8	53
271	Documentation of off-label use of biologics in Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii35-ii51.	0.5	7
273	Allogeneic Mesenchymal Stem Cell Transplantation in Severe and Refractory Systemic Lupus Erythematosus: 4 Years of Experience. <i>Cell Transplantation</i> , 2013, 22, 2267-2277.	1.2	213
274	The Musculoskeletal System and Bone Metabolism. , 2013, , 333-340.		3
276	CD20 Antibody Primes B Lymphocytes for Type I Interferon Production. <i>PLoS ONE</i> , 2013, 8, e67900.	1.1	5
277	Targeting the B-Cell Pathway in Lupus Nephritis: Current Evidence and Future Perspectives. <i>Scientific World Journal</i> , The, 2013, 2013, 1-5.	0.8	4
278	Pediatric lupus nephritis: Management update. <i>World Journal of Nephrology</i> , 2014, 3, 16.	0.8	32
279	Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus. <i>Drug Design, Development and Therapy</i> , 2014, 8, 2303.	2.0	8
280	Hepatic Manifestations in Juvenile Systemic Lupus Erythematosus. <i>Recent Patents on Inflammation and Allergy Drug Discovery</i> , 2014, 8, 36-40.	3.9	8

#	ARTICLE	IF	CITATIONS
281	Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus. <i>Immunotherapy</i> , 2014, 6, 1165-1175.	1.0	8
282	Successful application of belimumab in two patients with systemic lupus erythematosus experiencing a flare during tocilizumab treatment. <i>Lupus</i> , 2014, 23, 428-430.	0.8	9
283	Variability of the impact of adverse events on physicians' decision making. <i>BMC Medical Informatics and Decision Making</i> , 2014, 14, 86.	1.5	5
284	Immune checkpoint receptors in regulating immune reactivity in rheumatic disease. <i>Arthritis Research and Therapy</i> , 2014, 16, 469.	1.6	55
285	Plasmapheresis in a patient with antiphospholipid syndrome before living-donor kidney transplantation: a case report. <i>BMC Nephrology</i> , 2014, 15, 167.	0.8	5
286	Sirukumab: a novel therapy for lupus nephritis?. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1449-1455.	1.9	18
287	Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside. <i>Autoimmunity Highlights</i> , 2014, 5, 33-45.	3.9	32
288	Proteasome inhibitors in progressive renal diseases. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, i25-i30.	0.4	24
289	Systemic Lupus Erythematosus, Treatment. , 2014, , 1184-1188.		0
290	Use of rituximab as a treatment for systemic lupus erythematosus: retrospective review. <i>Einstein (Sao) TJ ETQq1 1 0.784314 16 BT /Over</i>	0.3	16
291	The Off-Label Use of Rituximab for the Management of Inflammatory Disorders: American University of Beirut Medical Center Experience. <i>Archives of Rheumatology</i> , 2014, 29, 194-202.	0.3	2
292	Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 473-489.	1.5	58
293	An overview of current and future treatment methods for lupus nephritis. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 169-179.	0.5	0
294	The potential role of blisibimod for the treatment of systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 121-134.	0.3	2
295	Understanding the role of B cells in atherosclerosis: potential clinical implications. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 77-89.	1.3	22
296	Pathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin. <i>Lupus Science and Medicine</i> , 2014, 1, e000013.	1.1	5
297	Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 311-326.	1.4	13
299	Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 183-190.	0.5	266

#	ARTICLE	IF	CITATIONS
300	Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome. <i>Muscle and Nerve</i> , 2014, 49, 325-328.	1.0	2
301	Interleukin-10-Producing B Cells and the Regulation of Immunity. <i>Current Topics in Microbiology and Immunology</i> , 2014, 380, 69-92.	0.7	38
302	Vasculitic Neuropathies and Neuropathies of Connective Tissue Diseases. , 2014, , 733-785.		4
303	Update on Rituximab: An Established Treatment for All Immune-Mediated Kidney Diseases?. <i>Nephron Clinical Practice</i> , 2014, 126, 97-109.	2.3	8
304	The pathogenesis, diagnosis and treatment of lupus nephritis. <i>Current Opinion in Rheumatology</i> , 2014, 26, 502-509.	2.0	103
305	Advances in the assessment of lupus disease activity and damage. <i>Current Opinion in Rheumatology</i> , 2014, 26, 510-519.	2.0	28
306	The management of lupus nephritis. <i>Nurse Practitioner</i> , 2014, 39, 1-6.	0.2	2
307	Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases. <i>Immunotherapy</i> , 2014, 6, 1207-1220.	1.0	26
308	Rituximab Therapy for Refractory Orbital Inflammation. <i>JAMA Ophthalmology</i> , 2014, 132, 572.	1.4	59
309	Systemic Lupus Erythematosus, Animal Models. , 2014, , 1134-1141.		0
310	Personalized Healthcare in Autoimmune Diseases. , 2014, , 51-71.		1
311	Republished: New age of biological therapies in paediatric rheumatology. <i>Postgraduate Medical Journal</i> , 2014, 90, 590-596.	0.9	1
312	Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus. <i>Autoimmune Diseases</i> , 2014, 2014, 1-4.	2.7	11
313	Risk of malignancy associated with biologic agents in pediatric rheumatic disease. <i>Current Opinion in Rheumatology</i> , 2014, 26, 538-542.	2.0	15
314	Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 175-185.	1.6	101
315	Efficacy and Safety of Biologic Therapies for Systemic Lupus Erythematosus Treatment: Systematic Review and Meta-Analysis. <i>BioDrugs</i> , 2014, 28, 211-228.	2.2	27
316	In-/off-label use of biologic therapy in systemic lupus erythematosus. <i>BMC Medicine</i> , 2014, 12, 30.	2.3	21
317	Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab. <i>Clinical Rheumatology</i> , 2014, 33, 799-805.	1.0	35

#	ARTICLE	IF	CITATIONS
318	Long-Term B Cell Depletion in Murine Lupus Eliminates Autoantibody-Secreting Cells and Is Associated with Alterations in the Kidney Plasma Cell Niche. <i>Journal of Immunology</i> , 2014, 192, 3011-3020.	0.4	30
319	In Search of Magic Bullets: The Golden Age of Immunotherapeutics. <i>Cell</i> , 2014, 157, 227-240.	13.5	40
320	Editorial: Plasma and B Cell Gene Signatures: Quantitative Targeting and Monitoring of B Cell Depleting Therapies in Autoimmune Diseases in the Genomic Era. <i>Arthritis and Rheumatology</i> , 2014, 66, 10-14.	2.9	26
321	A CD8 T Cell/Indoleamine 2,3-Dioxygenase Axis Is Required for Mesenchymal Stem Cell Suppression of Human Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2014, 66, 2234-2245.	2.9	86
322	General Features of Autoimmune Disease. , 2014, , 19-37.		11
323	Treatment of Autoimmune Disease. , 2014, , 1209-1220.		0
324	Treatment of Autoimmune Disease. , 2014, , 1221-1245.		2
326	Taking a closer look at biologic therapy for SLE. <i>Nature Reviews Rheumatology</i> , 2014, 10, 71-72.	3.5	10
327	Anti-B Cell Antibody Therapies for Inflammatory Rheumatic Diseases. <i>Annual Review of Medicine</i> , 2014, 65, 263-278.	5.0	33
328	Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys. <i>Nature Reviews Rheumatology</i> , 2014, 10, 23-34.	3.5	50
329	Lupus Nephritis: The Evolving Role of Novel Therapeutics. <i>American Journal of Kidney Diseases</i> , 2014, 63, 677-690.	2.1	87
330	Severe Skin Diseases in Children. , 2014, , .		0
331	Interleukin-10 in Health and Disease. <i>Current Topics in Microbiology and Immunology</i> , 2014, , .	0.7	13
332	The efficacy of novel B cell biologics as the future of SLE treatment: A review. <i>Autoimmunity Reviews</i> , 2014, 13, 1094-1101.	2.5	97
333	The quest for personalized B-cell depletion therapy in rheumatic disease. <i>Arthritis Research and Therapy</i> , 2014, 16, 116.	1.6	2
335	Rituximab, a viable alternative for induction therapy of active lupus nephritis. <i>Rheumatology</i> , 2014, 53, 1537-1538.	0.9	2
336	Belimumab in Systemic Lupus Erythematosus - What Can Be Learned from Longterm Observational Studies?. <i>Journal of Rheumatology</i> , 2014, 41, 192-193.	1.0	3
337	Response to: "Which B-cell subset should we target in lupus?" by Ferraccioli and Houssiau. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e20-e20.	0.5	3

#	ARTICLE	IF	CITATIONS
338	Rituximab and Lupus – A Promising Pair?. <i>Current Rheumatology Reports</i> , 2014, 16, 444.	2.1	7
339	Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus. <i>Journal of Dermatology</i> , 2014, 41, 418-420.	0.6	23
340	Measuring flares in systemic lupus erythematosus. <i>Rheumatology</i> , 2014, 53, 2134-2135.	0.9	6
341	Biologics in systemic lupus erythematosus: current options and future perspectives. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2014, 75, 440-447.	0.2	7
342	Preventing Autoimmunity Protects Against the Development of Hypertension and Renal Injury. <i>Hypertension</i> , 2014, 64, 792-800.	1.3	75
343	New insights into the pathogenesis and management of lupus in children. <i>Archives of Disease in Childhood</i> , 2014, 99, 563-567.	1.0	27
344	Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. <i>Arthritis Research and Therapy</i> , 2014, 16, R79.	1.6	244
345	Recent advances in the treatment of systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 89-100.	0.3	0
346	Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. <i>Rheumatology</i> , 2014, 53, 1570-1577.	0.9	76
347	Update on B-cell targeted therapies for systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 773-788.	1.4	6
348	New age of biological therapies in paediatric rheumatology. <i>Archives of Disease in Childhood</i> , 2014, 99, 679-685.	1.0	18
349	Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2014, 54, 60-71.	3.0	39
350	The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 178.	0.8	116
351	Molecular abnormalities of the B cell in systemic lupus erythematosus are candidates for functional inhibition treatments. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 833-840.	0.9	14
352	Hormonal milieu at time of B cell activation controls duration of autoantibody response. <i>Journal of Autoimmunity</i> , 2014, 53, 46-54.	3.0	26
353	Emerging biological therapies for systemic lupus erythematosus. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 303-322.	1.0	21
354	Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 491-501.	1.4	10
355	Anti-CD79 Antibody Induces B Cell Anergy That Protects against Autoimmunity. <i>Journal of Immunology</i> , 2014, 192, 1641-1650.	0.4	35

#	ARTICLE	IF	CITATIONS
356	Systemic lupus erythematosus. <i>Lancet, The</i> , 2014, 384, 1878-1888.	6.3	639
357	When biologics should be used in systemic lupus erythematosus?. <i>Presse Medicale</i> , 2014, 43, e181-e185.	0.8	5
358	Retinal vasculopathy in systemic lupus erythematosus: A case of lupus vasculitis and a case of non-vasculitis venous occlusion. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2014, 89, 66-69.	0.1	2
359	Impact of Race and Ethnicity in the Course and Outcome of Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, 433-454.	0.8	58
360	The Incidence and Risk Factors of Infusion-Related Reactions to Rituximab for Treating B Cell Malignancies in a Single Tertiary Hospital. <i>Oncology</i> , 2014, 86, 127-134.	0.9	25
361	Variability in clinical and biological response to rituximab in autoimmune diseases: an opportunity for personalized therapy?. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 279-293.	0.3	7
363	New therapeutic avenues in SLE. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 794-809.	1.4	11
364	Systemic lupus erythematosus and the role of the GP. <i>The Prescriber</i> , 2015, 26, 31-35.	0.1	0
365	Rituximab-containing Chemotherapy (R-CHOP)-induced Kaposi's Sarcoma in an HIV-negative Patient with Diffuse Large B Cell Lymphoma. <i>Internal Medicine</i> , 2015, 54, 3205-3208.	0.3	12
366	Placebo controlled trials in neuromyelitis optica are needed and ethical. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 536-545.	0.9	10
367	Rituximab treatment for nonparaneoplastic autoimmune retinopathy. <i>Canadian Journal of Ophthalmology</i> , 2015, 50, e101-e104.	0.4	21
368	Approaches for estimating minimal clinically important differences in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015, 17, 143.	1.6	180
370	Biologic therapies in systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 146-153.	0.9	11
371	Systemic lupus erythematosus. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2015, 28, 22-28.	0.1	1
372	Molecular Subsetting of Interferon Pathways in Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2015, 67, 2437-2446.	2.9	115
373	Ocular involvement in systemic lupus erythematosus. <i>Current Opinion in Ophthalmology</i> , 2015, 26, 540-545.	1.3	28
374	Biologic Therapeutic Agents in Nephrology. <i>Giornale De Tecniche Nefrologiche & Dialitiche</i> , 2015, 27, 214-220.	0.1	0
375	Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2015, 6, 550.	2.2	118

#	ARTICLE	IF	CITATIONS
376	Paradoxical Effects of All-Trans-Retinoic Acid on Lupus-Like Disease in the MRL/lpr Mouse Model. <i>PLoS ONE</i> , 2015, 10, e0118176.	1.1	42
377	Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis. <i>PLoS ONE</i> , 2015, 10, e0140843.	1.1	18
378	Profile of atacicept and its potential in the treatment of systemic lupus erythematosus. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1331.	2.0	29
379	Effect of TACI Signaling on Humoral Immunity and Autoimmune Diseases. <i>Journal of Immunology Research</i> , 2015, 2015, 1-12.	0.9	57
380	Upcoming biological therapies in systemic lupus erythematosus. <i>International Immunopharmacology</i> , 2015, 27, 189-193.	1.7	14
381	B cells biology in systemic lupus erythematosusâ€”from bench to bedside. <i>Science China Life Sciences</i> , 2015, 58, 1111-1125.	2.3	11
382	Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2015, 7, 234-246.	1.2	5
383	Efficacy and safety of rituximab in the treatment of primary antiphospholipid syndrome: Analysis of 24 cases from the bibliography review. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 97-104.	0.1	12
384	The use of unequal randomisation in clinical trials â€” An update. <i>Contemporary Clinical Trials</i> , 2015, 45, 113-122.	0.8	38
386	Belimumab for the treatment of systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 195-204.	1.3	21
387	Ofatumumab: a novel treatment for severe systemic lupus erythematosus. <i>Rheumatology</i> , 2015, 54, 559-560.	0.9	31
388	The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2015, 34, 263-271.	1.0	17
389	Effect of Rituximab on Serum Levels of Anti-C1q and Antineutrophil Cytoplasmic Autoantibodies in Refractory Severe Lupus Nephritis. <i>Cell Biochemistry and Biophysics</i> , 2015, 72, 197-201.	0.9	37
390	B cells take the front seat: dysregulated B cell signals orchestrate loss of tolerance and autoantibody production. <i>Current Opinion in Immunology</i> , 2015, 33, 70-77.	2.4	51
391	Suppression of FcÎ³-3-Receptor-Mediated Antibody Effector Function during Persistent Viral Infection. <i>Immunity</i> , 2015, 42, 379-390.	6.6	58
392	Rituximab: the Lupus Journey. <i>Current Treatment Options in Rheumatology</i> , 2015, 1, 30-41.	0.6	16
393	Biologics for the treatment of systemic lupus erythematosus: current status and emerging therapies. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 109-116.	1.3	41
395	What is new in the management of rapidly progressive glomerulonephritis?. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 143-150.	1.4	39

#	ARTICLE	IF	CITATIONS
396	Efficacy and safety of rituximab in rheumatic diseases. Wiener Medizinische Wochenschrift, 2015, 165, 28-35.	0.5	9
397	The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. Autoimmunity Reviews, 2015, 14, 1079-1086.	2.5	59
398	Editorial: The BAFFling Immunology of Systemic Lupus Erythematosus: Beyond B Cells. Arthritis and Rheumatology, 2015, 67, 612-615.	2.9	6
399	Genetics and novel aspects of therapies in systemic lupus erythematosus. Autoimmunity Reviews, 2015, 14, 1005-1018.	2.5	72
400	Longer duration of B cell depletion is associated with better outcome. Rheumatology, 2015, 54, 1876-1881.	0.9	21
401	Pathogenesis of Renal Disease in Systemic Lupus Erythematosus—The Role of Autoantibodies and Lymphocytes Subset Abnormalities. International Journal of Molecular Sciences, 2015, 16, 7917-7931.	1.8	60
402	Lupus Nephritis Clinical Trials: A Critical Appraisal. , 2015, , 17-31.		0
403	Biotherapies targeting T and B cells: from immune suppression to immune tolerance. Current Opinion in Pharmacology, 2015, 23, 92-97.	1.7	13
404	The evolution of drug discovery in systemic lupus erythematosus. Nature Reviews Rheumatology, 2015, 11, 616-620.	3.5	52
405	Is SLE many single-organ diseases or an overlapping spectrum?. Nature Reviews Rheumatology, 2015, 11, 385-386.	3.5	9
406	Manipulation of B-cell responses with histone deacetylase inhibitors. Nature Communications, 2015, 6, 6838.	5.8	73
407	Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2015, 18, 208-218.	0.9	19
409	Polychromatic flow cytometry in evaluating rheumatic disease patients. Arthritis Research and Therapy, 2015, 17, 46.	1.6	21
410	Rituximab and its therapeutic potential in catastrophic antiphospholipid syndrome. Therapeutic Advances in Musculoskeletal Disease, 2015, 7, 26-30.	1.2	20
411	Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus. Immunotherapy, 2015, 7, 255-270.	1.0	6
412	Reviewing the Recommendations for Lupus in Children. Current Rheumatology Reports, 2015, 17, 17.	2.1	12
413	Treatment Algorithms in Systemic Lupus Erythematosus. Arthritis Care and Research, 2015, 67, 1237-1245.	1.5	88
414	Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2015, 67, 2046-2055.	2.9	59

#	ARTICLE	IF	CITATIONS
415	Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE. <i>Lupus Science and Medicine</i> , 2015, 2, e000080-e000080.	1.1	103
416	Belimumab in systemic lupus erythematosus. <i>RMD Open</i> , 2015, 1, e000011-e000011.	1.8	20
417	Lupus eritematoso sist�mico. <i>EMC - Aparato Locomotor</i> , 2015, 48, 1-17.	0.1	1
420	Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: a literature review. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1373-1385.	1.0	21
421	Treatment of systemic lupus erythematosus patients with the BAFF antagonist �ceptibody�blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. <i>Arthritis Research and Therapy</i> , 2015, 17, 215.	1.6	48
422	B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use. <i>Current Rheumatology Reports</i> , 2015, 17, 65.	2.1	16
423	Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1635-1645.	1.5	3
425	Mycophenolate mofetil for lupus nephritis: an update. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 1353-1364.	1.3	37
426	Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2006-2015.	0.5	231
427	Rituximab in antiphospholipid syndrome: Always, never, sometimes?. <i>Medicina Cl�nica (English Edition)</i> , 2015, 144, 115-117.	0.1	0
428	Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis. <i>Seminars in Nephrology</i> , 2015, 35, 509-520.	0.6	24
430	Current role of rituximab in systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 154-163.	0.9	53
431	An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins Lupus Cohort. <i>Rheumatology</i> , 2015, 54, 623-632.	0.9	19
432	Vaccination of patients with autoimmune inflammatory rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2015, 11, 135-145.	3.5	64
433	The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. <i>Lupus</i> , 2015, 24, 10-17.	0.8	70
434	Safety of off-label biologics in systemic lupus erythematosus. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 243-251.	1.0	9
435	High-risk pregnancy and the rheumatologist. <i>Rheumatology</i> , 2015, 54, 572-587.	0.9	66
436	Rituximab in Systemic Lupus Erythematosus and Lupus Nephritis. <i>Nephron Clinical Practice</i> , 2015, 128, 250-254.	2.3	37

#	ARTICLE	IF	CITATIONS
437	Rituximab in Primary Membranous Nephropathy: First-Line Therapy, Why Not?. Nephron Clinical Practice, 2015, 128, 261-269.	2.3	43
439	Cell-based therapies for systemic lupus erythematosus. Autoimmunity Reviews, 2015, 14, 43-48.	2.5	28
441	'That Obscure Object of Desire': in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians. Nephrology Dialysis Transplantation, 2015, 30, 394-400.	0.4	4
442	Childhood onset systemic lupus erythematosus: how is it different from adult <scp>SLE</scp>?. International Journal of Rheumatic Diseases, 2015, 18, 182-191.	0.9	63
443	Glomerulonephritis â€œ Do We Have Promising Role of Monoclonal Antibodies?. Journal of Clinical & Experimental Nephrology, 2016, 01, .	0.1	0
445	Ovarian Functions and Reproductive Preservation in Patients with Systemic Lupus Erythematosus: A Review of Literature. Journal of Fertilization in Vitro IVF Worldwide Reproductive Medicine Genetics & Stem Cell Biology, 2016, 04, .	0.2	0
446	Rituximab in autoimmune diseases. Australian Prescriber, 2016, 39, 131-134.	0.5	72
447	Repositioning Drugs for Systemic Lupus Erythematosus. , 2016, , 567-575.		2
448	New Treatments for Systemic Lupus Erythematosus. , 2016, , 551-557.		3
449	The Impact of T Cell Vaccination in Alleviating and Regulating Systemic Lupus Erythematosus Manifestation. Journal of Immunology Research, 2016, 2016, 1-9.	0.9	3
450	Oxidative Stress in Systemic Lupus Erythematosus. , 2016, , 237-242.		0
451	Biologic Therapy in Inflammatory Immunomediated Systemic Diseases: Safety Profile. Current Drug Safety, 2016, 11, 44-46.	0.3	0
452	Current and emerging treatment options in the management of lupus. ImmunoTargets and Therapy, 2016, 5, 9.	2.7	32
453	Pathogenesis and treatment of glomerulonephritis-an update. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2016, 38, 107-22.	0.4	23
454	Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?. Drug Discovery Today, 2016, 21, 1330-1338.	3.2	33
455	Immunomodulators in SLE: Clinical evidence and immunologic actions. Journal of Autoimmunity, 2016, 74, 73-84.	3.0	71
456	Targeting plasma cells: are we any closer to a panacea for diseases of antibodyâ€™secreting cells?. Immunological Reviews, 2016, 270, 78-94.	2.8	10
457	Editorial: A Stalemate in Lupusâ€™Related Endâ€™Stage Renal Disease: Can We Do Better?. Arthritis and Rheumatology, 2016, 68, 1323-1326.	2.9	4

#	ARTICLE	IF	CITATIONS
458	Rare Presentation of Lupus Myocarditis With Acute Heart Failure—A Case Report. <i>American Journal of Therapeutics</i> , 2016, 23, e1952-e1955.	0.5	7
459	Single-dose rituximab in refractory lupus nephritis. <i>Internal Medicine Journal</i> , 2016, 46, 899-901.	0.5	17
460	Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis. <i>Journal of Autoimmunity</i> , 2016, 74, 94-105.	3.0	42
461	Off-label use of rituximab for systemic lupus erythematosus in Europe. <i>Lupus Science and Medicine</i> , 2016, 3, e000163.	1.1	51
462	TAC-TIC use of tacrolimus-based regimens in lupus nephritis. <i>Lupus Science and Medicine</i> , 2016, 3, e000169.	1.1	24
463	From BLISS to ILLUMINATE studies: “Blys repetita placenta”: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e10-e10.	0.5	2
464	Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia. <i>Haematologica</i> , 2016, 101, 1327-1332.	1.7	9
465	The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus. <i>Rheumatology</i> , 2017, 56, kew399.	0.9	91
466	It hasn't gone away: the problem of glucocorticoid use in lupus remains. <i>Rheumatology</i> , 2016, 56, kew406.	0.9	43
467	Update on clinical trials in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2016, 28, 477-487.	2.0	51
470	EXPLORER: une nouvelle perspective sur des anciennes données. <i>Revue Du Rhumatisme (Edition) Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	0.8	0
471	Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. <i>Cell</i> , 2016, 165, 551-565.	13.5	524
472	The safety of pharmacological treatment options for lupus nephritis. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1041-1054.	1.0	7
473	Recent advances and current state of immunotherapy in systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 927-939.	1.4	15
474	Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 723-733.	1.4	12
475	Connective Tissue Disease. <i>Rare Diseases of the Immune System</i> , 2016, , .	0.1	2
476	Risk of clinical deterioration in patients with lupus nephritis receiving rituximab. <i>Lupus</i> , 2016, 25, 1299-1306.	0.8	11
477	B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease. <i>Expert Review of Hematology</i> , 2016, 9, 553-561.	1.0	8

#	ARTICLE	IF	CITATIONS
478	Innovative Therapies in Systemic Lupus Erythematosus. <i>Rare Diseases of the Immune System</i> , 2016, , 239-261.	0.1	0
480	Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway. <i>Clinical and Translational Immunology</i> , 2016, 5, e79.	1.7	72
481	From old concerns to new advances and personalized medicine in lupus: The end of the tunnel is approaching. <i>Journal of Autoimmunity</i> , 2016, 74, 1-5.	3.0	15
482	Beyond pan-B-cell-directed therapy “ new avenues and insights into the pathogenesis of SLE. <i>Nature Reviews Rheumatology</i> , 2016, 12, 645-657.	3.5	69
483	Why targeted therapies are necessary for systemic lupus erythematosus. <i>Lupus</i> , 2016, 25, 1070-1079.	0.8	19
484	Improved strategies for designing lupus trials with targeted therapies: learning from 65 years of experience. <i>Lupus</i> , 2016, 25, 1141-1149.	0.8	6
485	Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus. <i>Lupus</i> , 2016, 25, 1086-1096.	0.8	21
486	A critical review of clinical trials in systemic lupus erythematosus. <i>Lupus</i> , 2016, 25, 1122-1140.	0.8	56
487	Patient-reported outcomes in lupus clinical trials with biologics. <i>Lupus</i> , 2016, 25, 1111-1121.	0.8	25
488	Ofatumumab treatment in lupus nephritis patients. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 552-555.	1.4	40
489	B cell-independent contribution of BAFF to murine autoimmune disease. <i>Clinical Immunology</i> , 2016, 172, 111-116.	1.4	7
490	BAFF- and APRIL-targeted therapy in systemic autoimmune diseases. <i>Inflammation and Regeneration</i> , 2016, 36, 6.	1.5	42
491	Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1225-1238.	1.4	9
492	Clinical practice guidelines for systemic lupus erythematosus: Recommendations for general clinical management. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 413.e1-413.e14.	0.1	7
493	Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus. <i>Clinical Drug Investigation</i> , 2016, 36, 889-902.	1.1	6
494	The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. <i>Journal of Autoimmunity</i> , 2016, 74, 41-72.	3.0	132
495	Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease. <i>CKJ: Clinical Kidney Journal</i> , 2016, 10, sfw101.	1.4	36
497	Complex disease=complex trial? Lessons from a successful trial of anti-IFNÎ± in SLE. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1899-1901.	0.5	2

#	ARTICLE	IF	CITATIONS
498	Cytokine-producing B cells: a translational view on their roles in human and mouse autoimmune diseases. <i>Immunological Reviews</i> , 2016, 269, 130-144.	2.8	50
500	Update on Biologic Therapies for Systemic Lupus Erythematosus. <i>Current Rheumatology Reports</i> , 2016, 18, 44.	2.1	11
501	Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. <i>Journal of Autoimmunity</i> , 2016, 74, 182-193.	3.0	132
502	B-cell subsets, signaling and their roles in secretion of autoantibodies. <i>Lupus</i> , 2016, 25, 850-856.	0.8	54
503	T follicular helper (Tfh) cells in lupus: Activation and involvement in SLE pathogenesis. <i>European Journal of Immunology</i> , 2016, 46, 281-290.	1.6	121
505	Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review. <i>Clinical Rheumatology</i> , 2016, 35, 517-522.	1.0	37
507	Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus. <i>Paediatric Drugs</i> , 2016, 18, 181-195.	1.3	19
508	Interfering with baffled B cells at the lupus tollway: Promises, successes, and failed expectations. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1325-1333.	1.5	8
509	The Role of B Cells in Systemic Sclerosis. , 2016, , 173-185.		0
510	The BAFFling effects of rituximab in lupus: danger ahead?. <i>Nature Reviews Rheumatology</i> , 2016, 12, 367-372.	3.5	90
512	Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. <i>Drugs</i> , 2016, 76, 459-483.	4.9	150
513	Drugs in early clinical development for Systemic Lupus Erythematosus. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 573-583.	1.9	10
514	Les vaccinations dans les rhumatismes inflammatoires chroniques de l'adulte: le calendrier vaccinal et les recommandations en cas de traitement de fond classique et biologique. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2016, 83, 92-98.	0.0	0
515	Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational study. <i>Joint Bone Spine</i> , 2016, 83, 191-197.	0.8	4
516	Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity. <i>Rheumatology</i> , 2016, 55, 263-267.	0.9	84
517	Vaccinations in adults with chronic inflammatory joint disease: Immunization schedule and recommendations for patients taking synthetic or biological disease-modifying antirheumatic drugs. <i>Joint Bone Spine</i> , 2016, 83, 135-141.	0.8	42
518	Use of biologics in SLE: a review of the evidence from a clinical perspective. <i>Rheumatology</i> , 2016, 55, 775-779.	0.9	10
519	Systemic lupus erythematosus: An update for ophthalmologists. <i>Survey of Ophthalmology</i> , 2016, 61, 65-82.	1.7	29

#	ARTICLE	IF	CITATIONS
520	Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. <i>Modern Rheumatology</i> , 2016, 26, 80-86.	0.9	40
521	Rheumatic Diseases of Childhood. , 2016, , 112-123.e1.		1
522	CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 217-233.	2.9	6
523	Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus. <i>Clinical Pharmacokinetics</i> , 2017, 56, 107-125.	1.6	8
524	Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience Over 14 Years. <i>Arthritis Care and Research</i> , 2017, 69, 257-262.	1.5	57
526	Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics. <i>Annual Review of Immunology</i> , 2017, 35, 337-370.	9.5	69
527	Systemic lupus erythematosus. <i>Clinical Medicine</i> , 2017, 17, 78-83.	0.8	44
528	Novel Treatments in Lupus. <i>Current Rheumatology Reports</i> , 2017, 19, 10.	2.1	4
529	Biologic Therapies for Autoimmune and Connective Tissue Diseases. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 283-299.	0.7	24
530	The utility of monitoring peripheral blood lymphocyte subsets by flow cytometric analysis in patients with rheumatological diseases treated with rituximab. <i>Autoimmunity Reviews</i> , 2017, 16, 542-547.	2.5	4
531	Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. <i>Pediatric Nephrology</i> , 2017, 32, 1013-1021.	0.9	36
532	Altered expression of signalling lymphocyte activation molecule receptors in T-cells from lupus nephritis patientsâ€”a potential biomarker of disease activity. <i>Rheumatology</i> , 2017, 56, 1206-1216.	0.9	12
533	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 650-657.	2.5	32
534	Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications. <i>Current Treatment Options in Neurology</i> , 2017, 19, 19.	0.7	5
535	Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 384-396.	1.6	20
536	Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 677-692.	1.3	22
537	Failure of a systemic lupus erythematosus response index developed from clinical trial data: lessons examined and learned. <i>Lupus</i> , 2017, 26, 909-916.	0.8	7
538	Regulating STING in health and disease. <i>Journal of Inflammation</i> , 2017, 14, 11.	1.5	72

#	ARTICLE	IF	CITATIONS
539	Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients. <i>Arthritis and Rheumatology</i> , 2017, 69, 2029-2037.	2.9	74
540	Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective. <i>Trends in Molecular Medicine</i> , 2017, 23, 615-635.	3.5	328
541	Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. <i>Leukemia and Lymphoma</i> , 2017, 58, 2633-2641.	0.6	19
542	B cells and atherosclerosis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017, 312, H1060-H1067.	1.5	47
544	Lupus pathobiology based on genomics. <i>Immunogenetics</i> , 2017, 69, 1-12.	1.2	25
545	Biothérapies dans le lupus systémique: de nouvelles cibles. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017, 84, 23-30.	0.0	0
546	Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design. <i>Arthritis and Rheumatology</i> , 2017, 69, 785-790.	2.9	10
548	Transient BAFF Blockade Inhibits Type 1 Diabetes Development in Nonobese Diabetic Mice by Enriching Immunoregulatory B Lymphocytes Sensitive to Deletion by Anti-CD20 Cotherapy. <i>Journal of Immunology</i> , 2017, 199, 3757-3770.	0.4	26
550	Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 925-938.	1.3	12
551	European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1965-1973.	0.5	105
552	Renal-infiltrating CD11c+ cells are pathogenic in murine lupus nephritis through promoting CD4+ T cell responses. <i>Clinical and Experimental Immunology</i> , 2017, 190, 187-200.	1.1	24
553	An update on biomarker discovery and use in systemic sclerosis. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 823-833.	1.5	17
554	Efficacy and Safety of Rituximab in the Management of Pediatric Systemic Lupus Erythematosus: A Systematic Review. <i>Journal of Pediatrics</i> , 2017, 187, 213-219.e2.	0.9	43
555	Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury. <i>Scientific Reports</i> , 2017, 7, 2775.	1.6	44
556	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis), <i>TJ ETQq0 0 0 rgBT/Overlock 10 Tf 50 1</i>	2.5	107
557	Lupus nephritis and B-cell targeting therapy. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 951-962.	1.3	29
558	Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. <i>Autoimmunity Highlights</i> , 2017, 8, 12.	3.9	137
560	Drugs for discoid lupus erythematosus. <i>The Cochrane Library</i> , 2017, 2017, CD002954.	1.5	46

#	ARTICLE	IF	CITATIONS
561	Infectious complications of rituximab therapy in renal disease. CKJ: Clinical Kidney Journal, 2017, 10, 455-460.	1.4	31
562	Secondary antibody deficiency and immunoglobulin replacement. Hong Kong Bulletin on Rheumatic Diseases, 2017, 17, 1-5.	0.1	4
563	Additional Improvements in Clinical Response From Adjuvant Biologic Response Modifiers in Adults With Moderate to Severe Systemic Lupus Erythematosus Despite Immunosuppressive Agents: A Systematic Review and Meta-analysis. Clinical Therapeutics, 2017, 39, 1479-1506.e45.	1.1	12
564	Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2017, 76, 1829-1836.	0.5	90
565	Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nature Reviews Nephrology, 2017, 13, 483-495.	4.1	245
566	Treatment of membranous nephropathy: time for a paradigm shift. Nature Reviews Nephrology, 2017, 13, 563-579.	4.1	117
567	Immunotherapies in phase II and III trials for the treatment of systemic lupus erythematosus. Expert Opinion on Orphan Drugs, 2017, 5, 55-69.	0.5	1
568	Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis. Expert Review of Clinical Immunology, 2017, 13, 667-676.	1.3	14
569	S2k guideline for treatment of cutaneous lupus erythematosus " guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). Journal of the European Academy of Dermatology and Venereology, 2017, 31, 389-404.	1.3	117
570	Systemic lupus erythematosus: still a challenge for physicians. Journal of Internal Medicine, 2017, 281, 52-64.	2.7	61
571	Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-blind, Placebo-controlled Trials. Arthritis and Rheumatology, 2017, 69, 362-375.	2.9	189
572	A systematic review of patient-reported outcomes in patients with cutaneous lupus erythematosus. British Journal of Dermatology, 2017, 176, 52-61.	1.4	18
573	Biotherapies in systemic lupus erythematosus: New targets. Joint Bone Spine, 2017, 84, 267-274.	0.8	14
574	Rituximab Hypersensitivity: Evaluation, Desensitization, and Potential Mechanisms. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1564-1571.	2.0	34
575	Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. Lupus Science and Medicine, 2017, 4, e000239.	1.1	82
576	Juvenile-onset systemic lupus erythematosus (JSLE) " Pathophysiological concepts and treatment options. Best Practice and Research in Clinical Rheumatology, 2017, 31, 488-504.	1.4	62
578	A nationwide evaluation of off-label drug utilization in Turkey. Turkish Journal of Medical Sciences, 2017, 47, 1229-1238.	0.4	3
579	Current perspective on rituximab in rheumatic diseases. Drug Design, Development and Therapy, 2017, Volume 11, 2891-2904.	2.0	76

#	ARTICLE	IF	CITATIONS
580	Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date. <i>Drug Design, Development and Therapy</i> , 2017, Volume11, 747-757.	2.0	28
582	Interactions between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2017, 8, 294.	2.2	56
583	Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?. <i>Frontiers in Immunology</i> , 2017, 8, 1245.	2.2	124
584	Systemic lupus erythematosus: an update. <i>Medical Journal of Australia</i> , 2017, 206, 215-220.	0.8	38
585	Longitudinal analysis of quality of life in patients with undifferentiated connective tissue diseases. <i>Patient Related Outcome Measures</i> , 2017, Volume 8, 7-13.	0.7	11
586	HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus. <i>Arthritis Research and Therapy</i> , 2017, 19, 211.	1.6	44
587	Rituximab as First-Line Therapy in Severe Lupus Erythematosus with Neuropsychiatric and Renal Involvement: A Case-Report and Review of the Literature. <i>Journal of Clinical Case Reports</i> , 2017, 7, .	0.0	3
588	Cell-Targeted Biologics and Emerging Targets. , 2017, , 1020-1043.e4.		0
589	Treatment of Systemic Lupus Erythematosus. , 2017, , 1368-1388.e5.		3
590	Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016. <i>Internal Medicine Journal</i> , 2018, 48, 165-172.	0.5	9
591	Lupus community panel proposals for optimising clinical trials: 2018. <i>Lupus Science and Medicine</i> , 2018, 5, e000258.	1.1	62
593	The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2018, 91, 45-54.	3.0	125
594	Promising Treatment Alternatives. , 2018, , 155-168.		0
595	Mouse models of lupus: what they tell us and what they don't. <i>Lupus Science and Medicine</i> , 2018, 5, e000199.	1.1	112
596	The interplay between tuberculosis and systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2018, 30, 395-402.	2.0	35
597	Plasma Cell Depletion Attenuates Hypertension in an Experimental Model of Autoimmune Disease. <i>Hypertension</i> , 2018, 71, 719-728.	1.3	38
598	Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 221-239.	1.6	43
599	Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014). <i>Rheumatology</i> , 2018, 57, 337-344.	0.9	92

#	ARTICLE	IF	CITATIONS
600	Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. <i>American Journal of Hematology</i> , 2018, 93, 424-429.	2.0	56
601	Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 741-758.	3.0	39
602	Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. <i>Lupus</i> , 2018, 27, 802-811.	0.8	40
603	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. <i>Rheumatology</i> , 2018, 57, 470-479.	0.9	73
604	Systemic and Biologic Agents for Lupus Erythematosus. , 2018, , 377-390.		0
605	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <i>Rheumatology</i> , 2018, 57, e1-e45.	0.9	247
606	New Trials in Lupus and where Are we Going. <i>Current Rheumatology Reports</i> , 2018, 20, 34.	2.1	10
607	Antibody Therapy. , 2018, , .		0
608	Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. <i>Rheumatology</i> , 2018, 57, 1156-1161.	0.9	58
609	Epratuzumab for the treatment of systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 245-258.	1.3	31
611	Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients. <i>Arthritis Care and Research</i> , 2018, 70, 98-103.	1.5	26
613	Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus. <i>Lupus</i> , 2018, 27, 290-302.	0.8	21
614	Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 55, 352-367.	2.9	75
616	An era of biological treatment in systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2018, 37, 1-3.	1.0	13
617	Can we manage lupus nephritis without chronic corticosteroids administration?. <i>Autoimmunity Reviews</i> , 2018, 17, 4-10.	2.5	37
618	Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1224-1233.	1.4	86
619	SLE, An Overlooked Disease: Possibilities for Early Rescue by Early Diagnosis. , 2018, , .		0
620	Novel Treatments in Lupus. <i>Frontiers in Immunology</i> , 2018, 9, 2658.	2.2	37

#	ARTICLE	IF	CITATIONS
621	Outcomes of rituximab therapy in refractory lupus: A meta-analysis. <i>European Journal of Rheumatology</i> , 2018, 5, 118-126.	1.3	65
622	The long and the short of it: insights into the cellular source of autoantibodies as revealed by B cell depletion therapy. <i>Current Opinion in Immunology</i> , 2018, 55, 81-88.	2.4	37
623	Biologics in Inflammatory Immune-mediated Systemic Diseases. <i>Current Pharmaceutical Biotechnology</i> , 2018, 18, 1008-1016.	0.9	17
624	Ustekinumab: a promising new drug for SLE?. <i>Lancet, The</i> , 2018, 392, 1284-1286.	6.3	6
625	Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin. <i>Transfusion</i> , 2018, 58, 2729-2735.	0.8	37
626	Factors affecting quality of life in patients with systemic lupus erythematosus: important considerations and potential interventions. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 915-931.	1.3	45
627	Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus. <i>JAMA Dermatology</i> , 2018, 154, 1432.	2.0	46
628	The effectiveness and safety of biological therapeutics in juvenile-onset systemic lupus erythematosus (JSLE): a systematic review. <i>Lupus</i> , 2018, 27, 2135-2145.	0.8	13
629	Patient-reported outcome measures for use in clinical trials of SLE: a review. <i>Lupus Science and Medicine</i> , 2018, 5, e000279.	1.1	32
630	Comparison of Plasma Cytokine Levels before and after Treatment with Rituximab in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus-Associated Polyautoimmunity. <i>Revista Universitas Medica</i> , 2018, 59, 1-16.	0.0	6
631	Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus – distinct roles of BAFF and APRIL. <i>Lupus</i> , 2018, 27, 1470-1478.	0.8	24
632	TLR4⁺CXCR4⁺ plasma cells drive nephritis development in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1498-1506.	0.5	50
633	New insights into the role of renal resident cells in the pathogenesis of lupus nephritis. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 284-289.	0.7	24
634	Lupus Nephritis: Current Treatment Paradigm and Unmet Needs. <i>Reviews on Recent Clinical Trials</i> , 2018, 13, 105-113.	0.4	16
635	Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 989-996.	1.4	12
636	BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance. <i>Science Advances</i> , 2018, 4, eaas9944.	4.7	98
637	Past, Present, and Future of Rituximab – The World’s First Oncology Monoclonal Antibody Therapy. <i>Frontiers in Oncology</i> , 2018, 8, 163.	1.3	238
638	Recent advances in the management of systemic lupus erythematosus. <i>F1000Research</i> , 2018, 7, 970.	0.8	23

#	ARTICLE	IF	CITATIONS
639	Increase of MZB1 in B cells in systemic lupus erythematosus: proteomic analysis of biopsied lymph nodes. <i>Arthritis Research and Therapy</i> , 2018, 20, 13.	1.6	34
640	Anti-CD20 monoclonal antibodies: reviewing a revolution. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2820-2841.	1.4	68
641	Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1502-1509.	2.2	113
642	The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials. <i>Autoimmunity Reviews</i> , 2018, 17, 781-790.	2.5	59
643	Therapeutic Monoclonal Antibodies as Immunomodulators and Anti-Cancer Agents: Development, Evidence of Efficacy, Mechanisms of Actions, Adverse Effects. , 2018, , 291-341.		3
644	Monoclonal Anti-CD20 (B-Cell) Antibody and Autoimmune Diseases. , 2018, , 343-363.		0
645	Genotypes, phenotypes and treatment with immunomodulators in the rheumatic diseases. <i>Journal of Internal Medicine</i> , 2018, 284, 228-239.	2.7	1
646	The Impact of Belimumab and Rituximab on Health-Related Quality of Life in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019, 71, 811-821.	1.5	27
648	Emerging targets for the treatment of lupus erythematosus: There is no royal road to treating lupus. <i>Modern Rheumatology</i> , 2019, 29, 60-69.	0.9	12
649	Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review. <i>BioMed Research International</i> , 2019, 2019, 1-17.	0.9	41
650	Glucocorticoids—All-Rounders Tackling the Versatile Players of the Immune System. <i>Frontiers in Immunology</i> , 2019, 10, 1744.	2.2	170
651	Management of non-renal non-neurologic persistent lupus activity in real world patients from Argentina. <i>Lupus</i> , 2019, 28, 1167-1173.	0.8	1
652	Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study. <i>European Journal of Internal Medicine</i> , 2019, 67, 59-64.	1.0	32
653	<p>Management of refractory lupus nephritis: challenges and solutions</p>. <i>Open Access Rheumatology: Research and Reviews</i> , 2019, Volume 11, 179-188.	0.8	17
654	The Role of Immune Checkpoint Receptors in Regulating Immune Reactivity in Lupus. <i>Cells</i> , 2019, 8, 1213.	1.8	14
656	Rare variants in non-coding regulatory regions of the genome that affect gene expression in systemic lupus erythematosus. <i>Scientific Reports</i> , 2019, 9, 15433.	1.6	16
657	Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. <i>Clinical Immunology</i> , 2019, 209, 108274.	1.4	94
658	Treatment for refractory lupus nephritis: Rituximab vs triple target therapy. <i>Autoimmunity Reviews</i> , 2019, 18, 102406.	2.5	11

#	ARTICLE	IF	CITATIONS
659	Learning From Success and Failure: Biologics for Non-approved Skin Diseases. <i>Frontiers in Immunology</i> , 2019, 10, 1918.	2.2	17
660	Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis. <i>BMC Rheumatology</i> , 2019, 3, 32.	0.6	12
662	Cutaneous lupus erythematosus: A review of the literature. <i>International Journal of Women's Dermatology</i> , 2019, 5, 320-329.	1.1	24
663	Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019, 11, 1759720X1987430.	1.2	14
664	Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. <i>Frontiers in Immunology</i> , 2019, 10, 1990.	2.2	133
665	Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases. <i>Arthritis and Rheumatology</i> , 2019, 71, 1812-1823.	2.9	89
666	Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review. <i>Drugs</i> , 2019, 79, 1199-1215.	4.9	27
667	Mesenchymal stem cell therapy induces FLT3L and CD1c+ dendritic cells in systemic lupus erythematosus patients. <i>Nature Communications</i> , 2019, 10, 2498.	5.8	100
668	DÃ©jÃ Vu But New: Using T Cells to Deplete B Cells to Treat Lupus. <i>American Journal of Kidney Diseases</i> , 2019, 74, 708-710.	2.1	0
669	Management strategies and future directions for systemic lupus erythematosus in adults. <i>Lancet, The</i> , 2019, 393, 2332-2343.	6.3	319
670	Novel paradigms in systemic lupus erythematosus. <i>Lancet, The</i> , 2019, 393, 2344-2358.	6.3	363
671	Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients. <i>Arthritis and Rheumatology</i> , 2019, 71, 1670-1680.	2.9	22
672	Current Insights Into Systemic Lupus Erythematosus. , 2019, , 475-482.		0
673	Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. <i>BMJ Open</i> , 2019, 9, e025687.	0.8	81
674	Defective Regulatory B Cells Are Associated With Thyroid-Associated Ophthalmopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4067-4077.	1.8	11
675	Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	178
676	Tolerability and safety of long-term rituximab treatment in systemic inflammatory and autoimmune diseases. <i>Rheumatology International</i> , 2019, 39, 1083-1090.	1.5	20
677	Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis. <i>Arthritis Research and Therapy</i> , 2019, 21, 92.	1.6	32

#	ARTICLE	IF	CITATIONS
678	The Potential Use of Metformin, Dipyridamole, N-Acetylcysteine and Statins as Adjunctive Therapy for Systemic Lupus Erythematosus. <i>Cells</i> , 2019, 8, 323.	1.8	23
679	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 736-745.	0.5	1,265
680	Recognition and management of systemic lupus erythematosus. <i>The Prescriber</i> , 2019, 30, 13-20.	0.1	0
681	Real-world evidence in rheumatic diseases: relevance and lessons learnt. <i>Rheumatology International</i> , 2019, 39, 403-416.	1.5	22
682	Changing paradigms in the treatment of systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2019, 6, e000310.	1.1	40
683	B Cells as a Therapeutic Target in Paediatric Rheumatic Disease. <i>Frontiers in Immunology</i> , 2019, 10, 214.	2.2	18
684	Immune Profiling and Precision Medicine in Systemic Lupus Erythematosus. <i>Cells</i> , 2019, 8, 140.	1.8	34
685	B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. <i>Annals of Internal Medicine</i> , 2019, 170, 585.	2.0	60
686	1. Systemischer Lupus erythematosus. , 2019, , 1-54.		0
687	Steroid sparing effect: an essential element in assessing therapeutic efficacy in SLE: response to "Time to change the primary outcome of lupus trials" by Houssiau. <i>Annals of the Rheumatic Diseases</i> , 2019, 80, annrheumdis-2019-216113.	0.5	5
688	Bruton's Tyrosine Kinase (Btk) Inhibitor Tirabrutinib Prevents the Development of Murine Lupus. , 2019, 09, .		3
689	Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. <i>BMJ Open</i> , 2019, 9, e032569.	0.8	35
691	Moving Forward With Biologics in Lupus Nephritis. <i>Advances in Chronic Kidney Disease</i> , 2019, 26, 338-350.	0.6	7
692	B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis"Role in Pathogenesis and Effect of Immunosuppressive Treatments. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6231.	1.8	88
694	Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2019, 46, 166-175.	1.0	12
695	The relationship between remission and health-related quality of life in a cohort of SLE patients. <i>Rheumatology</i> , 2019, 58, 628-635.	0.9	36
696	Antinuclear Antibodies, Antibodies to DNA, Histones, and Nucleosomes. , 2019, , 355-365.		4
697	The Musculoskeletal System and Bone Metabolism. , 2019, , 407-417.		1

#	ARTICLE	IF	CITATIONS
698	Clinical Aspects of Antiphospholipid Syndrome. , 2019, , 532-542.		0
699	Clinical Markers, Metrics, Indices, and Clinical Trials. , 2019, , 614-630.		7
700	Targeted Therapies in SLE. , 2019, , 710-718.		0
701	Epidemiology and Management of Lupus Nephritis. , 2019, , 727-744.		7
702	Systemic lupus erythematosus: Diagnosis and clinical management. Journal of Autoimmunity, 2019, 96, 1-13.	3.0	405
703	Bulgarian rheumatology: science and practice in a cost-constrained environment. Rheumatology International, 2019, 39, 417-429.	1.5	11
704	Effector and regulatory B cells in immune-mediated kidney disease. Nature Reviews Nephrology, 2019, 15, 11-26.	4.1	85
705	Current challenges in the development of new treatments for lupus. Annals of the Rheumatic Diseases, 2019, 78, 729-735.	0.5	39
706	Rituximab in moderate to severe non-renal systemic lupus erythematosus: a reanalysis of the EXPLORER study. Annals of the Rheumatic Diseases, 2019, 78, 1007-1010.	0.5	8
707	Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus. Rheumatology, 2019, 58, 1353-1360.	0.9	14
708	Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Review of Clinical Immunology, 2019, 15, 383-389.	1.3	52
709	New therapeutic strategies in systemic lupus erythematosus management. Nature Reviews Rheumatology, 2019, 15, 30-48.	3.5	118
710	Regulatory and effector B cells: Friends or foes?. Journal of Dermatological Science, 2019, 93, 2-7.	1.0	84
711	Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder. Neurochemistry International, 2019, 130, 104347.	1.9	34
712	Rituximab in systemic autoimmune rheumatic diseases: indications and practical use. Acta Clinica Belgica, 2019, 74, 272-279.	0.5	31
713	Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus. Rheumatology, 2019, 58, 304-312.	0.9	28
714	Cyclophosphamide Versus Mycophenolate Versus Rituximab in Lupus Nephritis Remission Induction. Journal of Clinical Rheumatology, 2019, 25, 28-35.	0.5	16
715	Efectividad y seguridad de rituximab en el lupus eritematoso sistÃ©mico. Serie de casos. Experiencia de 2 centros. ReumatologÃ­a ClÃ­nica, 2020, 16, 391-395.	0.2	1

#	ARTICLE	IF	CITATIONS
717	Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy. <i>Rheumatology</i> , 2020, 59, 1347-1354.	0.9	28
718	General Features of Autoimmune Disease. , 2020, , 17-44.		8
719	Treatment of Autoimmune Disease: Established Therapies. , 2020, , 1415-1435.		0
720	Emerging Biological and Molecular Therapies in Autoimmune Disease. , 2020, , 1437-1457.		1
721	Development of Murine Systemic Lupus Erythematosus in the Absence of BAFF. <i>Arthritis and Rheumatology</i> , 2020, 72, 292-302.	2.9	6
722	Is There a Future for Anti-CD38 Antibody Therapy in Systemic Autoimmune Diseases?. <i>Cells</i> , 2020, 9, 77.	1.8	16
723	Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia. <i>Autoimmunity Reviews</i> , 2020, 19, 102466.	2.5	53
724	B cells targeting therapy in the management of systemic lupus erythematosus. <i>Immunological Medicine</i> , 2020, 43, 16-35.	1.4	21
725	Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: A systematic review. <i>Autoimmunity Reviews</i> , 2020, 19, 102453.	2.5	22
726	Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. <i>Nature Reviews Rheumatology</i> , 2020, 16, 32-52.	3.5	68
727	Biologic therapies for systemic lupus erythematosus: where are we now?. <i>Current Opinion in Rheumatology</i> , 2020, 32, 597-608.	2.0	8
728	Analysis of Trans-Ancestral SLE Risk Loci Identifies Unique Biologic Networks and Drug Targets in African and European Ancestries. <i>American Journal of Human Genetics</i> , 2020, 107, 864-881.	2.6	23
729	Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, S16-S116.	2.0	107
730	Novel strategies to target the humoral alloimmune response. <i>Hla</i> , 2020, 96, 667-680.	0.4	6
731	Increasing Ancestral Diversity in Systemic Lupus Erythematosus Clinical Studies. <i>Arthritis Care and Research</i> , 2020, , .	1.5	8
733	Rhupus: a systematic literature review. <i>Autoimmunity Reviews</i> , 2020, 19, 102612.	2.5	31
734	Lupus erythematosus 2020. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 494-501.	0.1	3
735	Assessing the expression of immunosuppressive cytokines in the newly diagnosed systemic lupus Erythematosus patients: a focus on B cells. <i>BMC Immunology</i> , 2020, 21, 58.	0.9	8

#	ARTICLE	IF	CITATIONS
736	Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment?. <i>Frontiers in Immunology</i> , 2020, 11, 603237.	2.2	33
737	Lupus nephritis: clinical presentations and outcomes in the 21st century. <i>Rheumatology</i> , 2020, 59, v39-v51.	0.9	100
738	Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. <i>Rheumatology</i> , 2020, 59, v69-v81.	0.9	69
739	Systemic Lupus Erythematosus. <i>Annals of Internal Medicine</i> , 2020, 172, ITC81-ITC96.	2.0	328
740	Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies. <i>Frontiers in Medicine</i> , 2020, 7, 553075.	1.2	7
741	Expert Perspective: An Evidence-Based Approach to Refractory Cutaneous Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020, 72, 1777-1785.	2.9	10
742	Systemic lupus erythematosus: an expert insight into emerging therapy agents in preclinical and early clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1151-1162.	1.9	6
743	Efficacy and safety of rituximab for systemic lupus erythematosus treatment: a meta-analysis. <i>African Health Sciences</i> , 2020, 20, 871-884.	0.3	4
744	Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1191-1201.	1.6	19
745	Low-dose rituximab therapy in steroid-refractory thrombocytopenia due to systemic lupus erythematosus. <i>Rheumatology International</i> , 2020, 40, 1717-1724.	1.5	10
746	Lupus eritematoso sist�mico 2020. <i>Medicina Cl�nica</i> , 2020, 155, 494-501.	0.3	26
747	Health-Related Quality of Life Measures in Adult Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020, 72, 577-592.	1.5	7
748	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020, 29, 1571-1593.	0.8	80
749	Phoenix from the flames: Rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis. <i>Autoimmunity Reviews</i> , 2020, 19, 102668.	2.5	35
750	A wide perspective of targeted therapies for precision medicine in autoimmune diseases. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 447-453.	0.4	3
751	Candidate drug replacements for quinacrine in cutaneous lupus erythematosus. <i>Lupus Science and Medicine</i> , 2020, 7, e000430.	1.1	7
752	Efficacy and safety of rituximab biosimilar in refractory lupus. <i>Lupus Science and Medicine</i> , 2020, 7, e000442.	1.1	4
753	Systemic lupus erythematosus and risk of infection. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 527-538.	1.3	44

#	ARTICLE	IF	CITATIONS
754	Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New. <i>Rheumatology and Therapy</i> , 2020, 7, 433-446.	1.1	100
755	The history of lupus throughout the ages. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1361-1369.	0.6	12
756	Are lupus animal models useful for understanding and developing new therapies for human SLE?. <i>Journal of Autoimmunity</i> , 2020, 112, 102490.	3.0	13
757	Human gingiva-derived mesenchymal stem cells are therapeutic in lupus nephritis through targeting of CD39 ^{hi} CD73 signaling pathway. <i>Journal of Autoimmunity</i> , 2020, 113, 102491.	3.0	27
758	Rituximab use as induction therapy for lupus nephritis: a systematic review. <i>Lupus</i> , 2020, 29, 892-912.	0.8	15
759	<p>Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE</p>. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 105-110.	2.7	29
760	Therapeutic peptides for the treatment of systemic lupus erythematosus: a place in therapy. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 845-867.	1.9	3
761	Risk Factors and Prevention of <i>Pneumocystis jirovecii</i> Pneumonia in Patients With Autoimmune and Inflammatory Diseases. <i>Chest</i> , 2020, 158, 2323-2332.	0.4	58
762	Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. <i>Clinical Microbiology Reviews</i> , 2020, 33, .	5.7	68
763	Biosimilars. <i>Lupus</i> , 2020, 29, 525-532.	0.8	3
764	State-of-the-art treatment of systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 465-471.	0.9	85
766	Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1474-1483.	0.4	42
767	Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents. <i>Frontiers in Medicine</i> , 2020, 7, 303.	1.2	59
768	B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice. <i>Frontiers in Medicine</i> , 2020, 7, 316.	1.2	50
769	Natural products action on pathogenic cues in autoimmunity: Efficacy in systemic lupus erythematosus and rheumatoid arthritis as compared to classical treatments. <i>Pharmacological Research</i> , 2020, 160, 105054.	3.1	9
770	The challenges in data integration " heterogeneity and complexity in clinical trials and patient registries of Systemic Lupus Erythematosus. <i>BMC Medical Research Methodology</i> , 2020, 20, 164.	1.4	9
771	Rapidly progressive course of pauci-immune pulmonary capillaritis in a 70-year-old Asian male refractory to immunosuppression and plasma exchange. <i>BMJ Case Reports</i> , 2020, 13, e233577.	0.2	2
772	Promotion of T Regulatory Cells in Mice by B Cells and BAFF. <i>Journal of Immunology</i> , 2020, 204, 2416-2428.	0.4	12

#	ARTICLE	IF	CITATIONS
773	New treatments of systemic lupus erythematosus. , 2021, , 629-639.		0
774	Which is the best SLE activity index for clinical trials?. Modern Rheumatology, 2021, 31, 20-28.	0.9	24
775	Patients with systemic lupus erythematosus show increased proportions of CD19+CD20 ^{hi} B cells and secretion of related autoantibodies. Clinical Rheumatology, 2021, 40, 151-165.	1.0	7
776	Measuring disease activity. , 2021, , 29-35.		0
777	Metabolic control of lupus pathogenesis: central role for activation of the mechanistic target of rapamycin. , 2021, , 267-276.		0
778	Repositioning drugs for systemic lupus erythematosus. , 2021, , 641-652.		0
779	Management of Severe Refractory Systemic Lupus Erythematosus: Real-World Experience and Literature Review. Clinical Reviews in Allergy and Immunology, 2021, 60, 17-30.	2.9	15
780	Response to placebo in non-renal, non-neuropsychiatric systemic lupus erythematosus: a systematic review and pooled analysis. Rheumatology, 2021, 60, 73-80.	0.9	3
781	Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis and Rheumatology, 2021, 73, 121-131.	2.9	117
782	Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies. Trends in Molecular Medicine, 2021, 27, 152-171.	3.5	34
783	Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy. Lupus, 2021, 30, 134-140.	0.8	5
784	A novel BAFF antagonist, BAFF-Trap, effectively alleviates the disease progression of systemic lupus erythematosus in MRL/lpr mice. Molecular Immunology, 2021, 129, 1-11.	1.0	2
785	Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus. Biologicals, 2021, 69, 1-14.	0.5	13
786	B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nature Reviews Drug Discovery, 2021, 20, 179-199.	21.5	296
787	Invariant natural killer T cells balance B cell immunity. Immunological Reviews, 2021, 299, 93-107.	2.8	2
788	Challenges of systemic lupus clinical trials. , 2021, , 673-682.		0
789	New developments in systemic lupus erythematosus. Rheumatology, 2021, 60, vi21-vi28.	0.9	16
790	Biologics Targeting Immune Modulation in Inflammatory Disorders. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
791	Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Therapeutics and Clinical Risk Management, 2021, Volume 17, 39-54.	0.9	38
792	Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease. Drugs in Context, 2021, 10, 1-12.	1.0	10
793	The peptide symporter SLC15a4 is essential for the development of systemic lupus erythematosus in murine models. PLoS ONE, 2021, 16, e0244439.	1.1	17
794	Metrics and Outcomes of SLE Clinical Trials. , 2021, , 371-390.		0
795	Rituximab – The first twenty years. Lupus, 2021, 30, 371-377.	0.8	16
796	Lupus Cerebritis Refractory to Guideline-Directed Therapy: A Case Report. Journal of Investigative Medicine High Impact Case Reports, 2021, 9, 232470962110087.	0.3	1
798	Biologic therapies for the treatment of systemic lupus erythematosus. Journal of the Korean Medical Association, 2021, 64, 109-115.	0.1	1
799	B Cell Aberrance in Lupus: the Ringleader and the Solution. Clinical Reviews in Allergy and Immunology, 2022, 62, 301-323.	2.9	12
800	Interventions for cutaneous disease in systemic lupus erythematosus. The Cochrane Library, 2021, 2021, CD007478.	1.5	12
801	Lupus Nephritis; Pathogenesis and Treatment Update Review. Open Science Journal, 2021, 6, .	0.2	2
802	Cell-Based Delivery Systems: Emerging Carriers for Immunotherapy. Advanced Functional Materials, 2021, 31, 2100088.	7.8	60
804	Stem Cell Therapy as a Treatment for Autoimmune Disease – Updates in Lupus, Scleroderma, and Multiple Sclerosis. Current Allergy and Asthma Reports, 2021, 21, 22.	2.4	9
805	Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic). Arthritis Research and Therapy, 2021, 23, 70.	1.6	12
806	Belimumab: a step forward in the treatment of systemic lupus erythematosus. Expert Opinion on Biological Therapy, 2021, 21, 563-573.	1.4	9
807	Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For musculoskeletal Lupus longitudinal multicentre study. Rheumatology, 2021, 60, 5194-5204.	0.9	16
808	Psychometric properties of FACIT-Fatigue in systemic lupus erythematosus: a pooled analysis of three phase 3 randomised, double-blind, parallel-group controlled studies (BLISS-SC, BLISS-52, BLISS-76). Journal of Patient-Reported Outcomes, 2021, 5, 33.	0.9	1
809	Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study. Rheumatology International, 2021, 41, 1115-1124.	1.5	13
810	Transcriptomic studies of systemic lupus erythematosus. Inflammation and Regeneration, 2021, 41, 11.	1.5	8

#	ARTICLE	IF	CITATIONS
811	Application features of biological therapy in patients with autoimmune diseases. <i>Minerva Biotechnology and Biomolecular Research</i> , 2021, 33, .	0.3	0
812	A Consensus for the Management of Systemic Lupus Erythematosus in Asia. <i>Journal of Clinical Rheumatology and Immunology</i> , 2021, 21, 1-6.	0.4	2
813	Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World. <i>Life</i> , 2021, 11, 457.	1.1	8
814	Current Status of the Evaluation and Management of Lupus Patients and Future Prospects. <i>Frontiers in Medicine</i> , 2021, 8, 682544.	1.2	5
815	The clinical efficacy of Rituximab administration in autoimmunity disorders, primary immunodeficiency diseases and malignancies. <i>International Immunopharmacology</i> , 2021, 95, 107565.	1.7	6
816	Treatment Update in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 513-530.	0.8	6
817	Meant to B: B cells as a therapeutic target in systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	27
818	Systemic Lupus Erythematosus Outcome Measures for Systemic Lupus Erythematosus Clinical Trials. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 415-426.	0.8	4
819	Rituximab use in pediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort. <i>Lupus</i> , 2021, 30, 1829-1836.	0.8	7
820	Molecular Signatures of Kidney Antibody-Secreting Cells in Lupus Patients With Active Nephritis Upon Immunosuppressive Therapy. <i>Arthritis and Rheumatology</i> , 2021, 73, 1461-1466.	2.9	10
821	Systemic Lupus Erythematosus Research: A Bibliometric Analysis over a 50-Year Period. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7095.	1.2	40
822	The landscape of systemic lupus erythematosus in Brazil: An expert panel review and recommendations. <i>Lupus</i> , 2021, 30, 1684-1695.	0.8	7
823	Can we predict if patients with SLE will require more than one cycle of rituximab?. <i>Rheumatology</i> , 2022, 61, 1892-1899.	0.9	4
824	First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis. <i>Arthritis Research and Therapy</i> , 2021, 23, 211.	1.6	12
825	Systemic lupus erythematosus: a clinical update. <i>Internal Medicine Journal</i> , 2021, 51, 1219-1228.	0.5	2
826	S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 2: Therapy, risk factors and other special topics. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1371-1395.	0.4	3
827	Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 1835-1846.	2.9	59
828	Novel Therapeutic Interventions in Systemic Lupus Erythematosus. , 0, , .		0

#	ARTICLE	IF	CITATIONS
829	B Cells in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 395-413.	0.8	12
830	Patient-Reported Outcomes for Quality of Life in SLE: Essential in Clinical Trials and Ready for Routine Care. <i>Journal of Clinical Medicine</i> , 2021, 10, 3754.	1.0	12
831	Innovative Trials and New Opportunities in SLE. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 481-499.	0.8	2
832	Clinician-reported outcome measures in lupus trials: a problem worth solving. <i>Lancet Rheumatology</i> , 2021, 3, e595-e603.	2.2	13
833	CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2021, 385, 567-569.	13.9	175
834	Immune Thrombocytopenia in Antiphospholipid Syndrome: Is It Primary or Secondary?. <i>Biomedicines</i> , 2021, 9, 1170.	1.4	14
835	The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 152-165.	2.9	12
836	S2 Leitlinie zur Diagnostik und Therapie des kutanen Lupus erythematosodes " Teil 2: Therapie, Risikofaktoren und spezielle Fragestellungen. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1371-1395.	0.4	2
837	Regulation of B cell functions by S-nitrosoglutathione in the EAE model. <i>Redox Biology</i> , 2021, 45, 102053.	3.9	11
838	Targeting B cells in the pre-phase of systemic autoimmunity globally interferes with autoimmune pathology. <i>IScience</i> , 2021, 24, 103076.	1.9	6
839	Abordaje terapéutico del síndrome pulmonar-riñón asociado con lupus eritematoso sistémico, una urgencia médica que es un reto para el clínico. <i>Revista Colombiana De Reumatología</i> , 2021, , .	0.0	0
840	Approaches to Establishing Tolerance in Immune Mediated Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 744804.	2.2	7
841	Is There a Place for Chimeric Antigen Receptor T Cells in the Treatment of Chronic Autoimmune Rheumatic Diseases?. <i>Arthritis and Rheumatology</i> , 2021, 73, 1954-1965.	2.9	28
842	Immunosuppressive therapy in SLE. , 2021, , 623-659.		0
843	Quantifying the effects of biopsy fixation and staining panel design on automatic instance segmentation of immune cells in human lupus nephritis. <i>Journal of Biomedical Optics</i> , 2021, 26, .	1.4	7
844	Cutaneous Lupus Erythematosus. , 0, , 547-558.		1
845	Systemic Lupus Erythematosus: Direct B-Cell Blocking. <i>Milestones in Drug Therapy</i> , 2014, , 65-78.	0.1	1
846	Stem Cell Therapy in the Treatment of Rheumatic Diseases and Application in the Treatment of Systemic Lupus Erythematosus. , 2017, , 167-198.		2

#	ARTICLE	IF	CITATIONS
847	Neue Arzneimittel 2011. , 2012, , 43-126.		1
848	Targeted Biologic Therapy for Systemic Lupus Erythematosus: Emerging Pathways and Drug Pipeline. BioDrugs, 2020, 34, 133-147.	2.2	25
849	B-cell depletion. , 2015, , 472-478.		2
850	Treatment of Systemic Lupus Erythematosus. , 2013, , 1304-1330.e6.		1
851	Effectiveness and safety of rituximab in systemic lupus erythematosus: A case series describing the experience of 2 centres. ReumatologĀa ClĀnica (English Edition), 2020, 16, 391-395.	0.2	1
853	Risk of adverse events from different drugs for SLE: a systematic review and network meta-analysis. Lupus Science and Medicine, 2018, 5, e000253.	1.1	18
854	Patient ancestry significantly contributes to molecular heterogeneity of systemic lupus erythematosus. JCI Insight, 2020, 5, .	2.3	47
855	B cells from African American lupus patients exhibit an activated phenotype. JCI Insight, 2016, 1, e87310.	2.3	37
856	Patrolling monocytes promote the pathogenesis of early lupus-like glomerulonephritis. Journal of Clinical Investigation, 2019, 129, 2251-2265.	3.9	70
857	mTOR has distinct functions in generating versus sustaining humoral immunity. Journal of Clinical Investigation, 2016, 126, 4250-4261.	3.9	123
858	Automated Detection of Off-Label Drug Use. PLoS ONE, 2014, 9, e89324.	1.1	47
859	PROSPECTS FOR ANTI-B-CELL THERAPY IN IMMUNO-INFLAMMATORY RHEUMATIC DISEASES. Nauchno-Prakticheskaya Revmatologiya, 0, 57, 1-40.	0.2	23
860	Use of rituximab in systemic lupus erythematosus in children: a review. Nauchno-Prakticheskaya Revmatologiya, 2019, 57, 578-583.	0.2	3
861	Systemic lupus erythematosus: new horizons for diagnosis and therapy. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 5-14.	0.2	16
862	A CASE REPORT OF RETINAL VASCULITIS IN SYSTEMIC LUPUS ERYTHEMATOSUS. Journal of Evidence Based Medicine and Healthcare, 2017, 4, 4503-4506.	0.0	1
863	The Influence of Different Disease States on Rituximab Pharmacokinetics. Current Drug Metabolism, 2020, 21, 938-946.	0.7	9
864	Lupus thrombocytopenia: pathogenesis and therapeutic implications. Mediterranean Journal of Rheumatology, 2017, 28, 20-26.	0.3	18
865	Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (S.E.N.). NefrologĀa, 2012, 32 Suppl 1, 1-35.	0.2	24

#	ARTICLE	IF	CITATIONS
866	Role of monoclonal antibodies in the treatment of immune-mediated glomerular diseases. <i>Nefrologia</i> , 2014, 34, 388-97.	0.2	8
867	Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial. <i>Health Technology Assessment</i> , 2017, 21, 1-374.	1.3	14
868	Advances in management of systemic lupus erythematosus. <i>Journal of Mahatma Gandhi Institute of Medical Sciences</i> , 2014, 19, 28.	0.1	1
869	Current status of lupus nephritis. <i>Indian Journal of Medical Research</i> , 2017, 145, 167-178.	0.4	17
870	From the Large Scale Expression Analysis of Lupus Nephritis to Targeted Molecular Medicine. <i>Journal of Data Mining in Genomics & Proteomics</i> , 2012, 03, .	0.5	10
871	Impact of standard of care treatments and disease variables on outcomes in systemic lupus erythematosus trials: analysis from the Lupus Foundation of America Collective Data Analysis Initiative. <i>European Journal of Rheumatology</i> , 2016, 3, 13-19.	1.3	11
872	Systemic Lupus Erythematosus: Recent Concepts in Genomics, Pathogenetic Mechanisms, and Therapies. <i>ISRN Immunology</i> , 2011, 2011, 1-7.	0.7	6
873	Biological therapies in rheumatic diseases. <i>Clinica Terapeutica</i> , 2013, 164, e413-28.	0.2	37
874	Measurement of specific organ domains in lupus randomized controlled trials: a scoping review. <i>Rheumatology</i> , 2022, 61, 1341-1353.	0.9	4
875	Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis. <i>Frontiers in Neurology</i> , 2021, 12, 736190.	1.1	17
876	B-Cell Targeted Therapeutics in Systemic Lupus Erythematosus: From Paradox to Synergy?. <i>Annals of Internal Medicine</i> , 2021, 174, 1747-1748.	2.0	2
877	Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus. <i>Annals of Internal Medicine</i> , 2021, 174, 1647-1657.	2.0	64
878	Targeted Therapies in Autoimmune and Inflammatory Skin Disorders. , 2011, , 537-570.		0
880	Update und neue technische Entwicklungen. <i>Fortschritte Der Praktischen Dermatologie Und Venerologie</i> , 2011, , 191-231.	0.0	0
881	The Emerging Role of Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus. , 0, , .		0
882	New and Emerging Therapies. , 2012, , 223-228.		0
883	Entzündliche GefÄÄÄrkrankungen. , 2012, , 335-398.		0
885	The Role of B-Cells and B-Cell Targeted Therapies in Lupus Nephritis. , 0, , .		0

#	ARTICLE	IF	CITATIONS
886	New Therapeutic Strategies in Lupus Nephritis. , 0, , .		0
887	Clinical Flow Cytometry - Emerging Applications. , 2012, , .		10
888	B Cells in Health and Disease " Leveraging Flow Cytometry to Evaluate Disease Phenotype and the Impact of Treatment with Immunomodulatory Therapeutics. , 0, , .		0
889	Developing novel drugs for systemic lupus erythematosus. Lessons learned from the belimumab trials. Reviews in Health Care, 2012, 3, 209-222.	0.1	0
890	Pharmacotherapy in Systemic Lupus Erythematosus. Current Rheumatology Reviews, 2012, 8, 166-179.	0.4	0
891	Quel est le risque infectieux viral d'un lupique ?. , 2013, , 173-182.		0
892	Comment je traite une atteinte articulaire r� fractaire aux AINS ?. , 2013, , 311-314.		0
893	Cell-Targeted Biologics and Targets. , 2013, , 978-1000.		0
894	Molecular targeted therapy as new options for childhood kidney diseases. Japanese Journal of Pediatric Nephrology, 2013, 26, 43-51.	0.0	0
895	Physiopathologie du lupus �ryth�mateux. , 2013, , 7-39.		0
896	Targeted Therapies in Systemic Lupus Erythematosus: A State-of-the Art Review. Journal of Clinical & Cellular Immunology, 2013, 01, .	1.5	0
898	Connective Tissue Disease. , 2014, , 91-122.		0
899	Systemic Lupus Erythematosus: Indirect B-Cell Blocking. Milestones in Drug Therapy, 2014, , 79-95.	0.1	0
900	TORCH-Infection and Its Possible Role in Syntropic Liver Damage in Patients with Systemic Lupus Erythematosus (literature review and clinical case description). Lviv Clinical Bulletin, 2013, 4, 43-51.	0.1	2
901	Nichtinfekti�s. , 2014, , 395-516.		0
902	Systemic Lupus Erythematosus, Clinical Trials. , 2014, , 1156-1161.		0
903	Systemic Lupus Erythematosus, Antiphospholipid Syndrome and the Kidney. , 2014, , 235-247.		0
904	Practical Immunosuppression Guidelines for Patients with Glomerulonephritis. , 2014, , 249-256.		0

#	ARTICLE	IF	CITATIONS
905	New possibilities of pharmacotherapy for systemic lupus erythematosus: A place of belimumab. <i>Sovremennaya Revmatologiya</i> , 2014, , 4.	0.1	0
906	Management of nonrenal and non-“central nervous system lupus. , 2015, , 1099-1106.		0
907	Bullous Diseases: Old Blisters with New Therapeutic Targets. , 2015, , 135-146.		0
908	Systemischer Lupus erythematosus. , 2015, , H6d.1-H6d.4.		1
909	Lupusnephritis. , 2015, , 1-3.		0
910	Assessing disease activity and outcome in systemic lupus erythematosus. , 2015, , 1093-1098.		0
911	Measuring Disease Activity. , 2016, , 23-29.		1
912	Integrating Current Thinking on Peripheral B-Cell Tolerance in Lupus. , 2016, , 121-126.		1
913	Lupus Nephritis. , 2016, , 759-780.		0
914	B Cells. , 2016, , 113-130.		0
915	Therapy of Immunobullous Disorders. , 2017, , 767-774.		0
916	Lupus and Lupus Overlap Diseases: Emerging Therapies. , 2017, , 474-494.		0
917	Lupus erythematosus. , 2017, , 1-18.		0
919	Treatments. , 2018, , 85-107.		0
920	Therapies in late-stage clinical development. , 2018, , 109-120.		0
921	Lupus erythematosus. , 2018, , 937-953.		1
922	Les vaccinations dans les rhumatismes inflammatoires chroniques de l'adulte. , 2018, , 601-608.		0
923	Vaccination for Patients with Rheumatic Diseases in the Era of Biologics. <i>Journal of Rheumatic Diseases</i> , 2018, 25, 100.	0.4	2

#	ARTICLE	IF	CITATIONS
924	The effects of rheumatoid arthritis on Cypriot recreational athletes. <i>Testnevel</i> 2019, 4, 23-41.	0.0	0
925	IMPACT OF THERAPY ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (ACCORDING TO THE RENAISSANCE REGISTER). <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2019, 57, 421-425.	0.2	1
926	10-Đ»ĐµÑ,Đ½Đ,Đ¹ Đ»Đ,Ñ±Đ½Ñ«Đ¹ Đ¾Đ;Ñ«Ñ, Đ;Ñ«Đ,Đ¼ĐµĐ½ĐµĐ½Đ,Ñ•Ñ«Đ,Ñ,ÑfĐ°ÑĐ,Đ¼Đ°Đ±Đ° Ñf Đ½ĐµÑ,Ñ«Đ¾Đ»Đ¾Đ³Đ³Đ		
928	Treatment of systemic lupus erythematosus. <i>Australian Prescriber</i> , 2020, 43, 85-90.	0.5	8
929	Treatment of Systemic Lupus Erythematosus. <i>Korean Journal of Medicine</i> , 2020, 95, 162-169.	0.1	2
931	The dawn of a new era of therapies in systemic lupus erythematosus. <i>Rheumatology and Immunology Research</i> , 2020, 1, 31-37.	0.2	3
932	Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?. <i>Rheumatology</i> , 2022, 61, 2894-2904.	0.9	9
936	Systemic lupus erythematosus and related disorders. , 2020, , 4499-4513.		0
938	Sequential therapy with rituximab and belimumab in patients with systemic lupus erythematosus. <i>Sovremennaya Revmatologiya</i> , 2020, 14, 31-38.	0.1	1
939	CAR-T cells leave the comfort zone: current and future applications beyond cancer. <i>Immunotherapy Advances</i> , 2021, 1, .	1.2	5
940	Lupus: an overview of the disease and management options. <i>P and T</i> , 2012, 37, 240-9.	1.0	56
941	Neuropsychiatric lupus. <i>Sultan Qaboos University Medical Journal</i> , 2013, 13, 19-25.	0.3	3
942	Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning?. <i>Discovery Medicine</i> , 2010, 10, 416-24.	0.5	24
943	A Systematic Review of the Economic Evaluations of Belimumab in Systemic Lupus Erythematosus. <i>Value in Health Regional Issues</i> , 2022, 27, 32-40.	0.5	1
944	Deconvoluting the heterogeneity of SLE: The contribution of ancestry. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 12-23.	1.5	11
945	Discovery of a novel Ig ^g 2 and Fc ^g 3RIIB cross-linking antibody, ASP2713, and its potential application in the treatment of systemic lupus erythematosus. <i>International Immunopharmacology</i> , 2021, 101, 108343.	1.7	0
948	Discovery and mechanistic study of thiazole-4-acylsulfonamide derivatives as potent and orally active ChemR23 inhibitors with a long-acting effect in cynomolgus monkeys. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 56, 116587.	1.4	1
950	Expanding the Role of CAR-T Cell Therapy to Systemic Lupus Erythematosus. <i>European Medical Journal Hematology</i> , 0, , 105-112.	0.0	3

#	ARTICLE	IF	CITATIONS
951	New Insights Into Systemic Lupus Erythematosus Therapies. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e217-e221.	0.5	2
952	Systemic lupus erythematosus and immunodeficiency. <i>Rheumatology and Immunology Research</i> , 2021, 2, 131-138.	0.2	3
953	Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 499-507.	1.4	6
955	Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. <i>Nature Reviews Rheumatology</i> , 2022, 18, 146-157.	3.5	55
956	Associations of lymphocyte subpopulations with clinical phenotypes and long-term outcomes in juvenile-onset systemic lupus erythematosus. <i>PLoS ONE</i> , 2022, 17, e0263536.	1.1	11
957	Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2022, , .	1.3	5
960	Biologic Agents and Other Emerging Therapies for Childhood SLE. <i>Pediatric Annals</i> , 2022, 51, e63-e71.	0.3	1
961	CAR-based therapies: opportunities for immuno-medicine beyond cancer. <i>Nature Metabolism</i> , 2022, 4, 163-169.	5.1	43
962	Rituximabâ€™a B cell targeted therapy in systemic lupus erythematosus: where do we stand?. <i>Rheumatology</i> , 2022, , .	0.9	2
963	Emerging therapeutics in the management of connective tissue disease. Part I. Lupus erythematosus and Sjögren syndrome. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1-18.	0.6	3
964	Rituximab in the real-world treatment of lupus nephritis: A retrospective cohort study in Japan. <i>Modern Rheumatology</i> , 2023, 33, 145-153.	0.9	6
965	T Cells, Interleukin-2 and Systemic Lupus Erythematosusâ€™From Pathophysiology to Therapy. <i>Cells</i> , 2022, 11, 980.	1.8	3
966	Small molecule inhibitors of nuclear export ameliorate lupus by modulating plasma cell generation and survival. <i>Arthritis and Rheumatology</i> , 2022, , .	2.9	1
967	Comparative Effectiveness of Rituximab and Common Induction Therapies for Lupus Nephritis: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 859380.	2.2	7
974	Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study. <i>Clinical Immunology</i> , 2022, 239, 109028.	1.4	6
975	Ovariectomy increases paclitaxel-induced mechanical hypersensitivity and reduces anti-inflammatory CD4+ T cells in the dorsal root ganglion of female mice. <i>Journal of Neuroimmunology</i> , 2022, 367, 577878.	1.1	5
976	Belimumab for systemic lupus erythematosus â€™ Focus on lupus nephritis. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2072143.	1.4	6
977	T cell help in the autoreactive germinal center. <i>Scandinavian Journal of Immunology</i> , 2022, 95, e13192.	1.3	4

#	ARTICLE	IF	CITATIONS
980	Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial. <i>Lupus Science and Medicine</i> , 2022, 9, e000584.	1.1	5
981	Acteoside promotes B cell-derived IL-10 production and ameliorates autoimmunity. <i>Journal of Leukocyte Biology</i> , 2022, 112, 875-885.	1.5	8
982	Measurement of circulating CD21 ⁺ CD27 ⁺ B lymphocytes in SLE patients is associated with disease activity independently of conventional serological biomarkers. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
983	Cytokine-producing B cell balance associates with skin fibrosis in patients with systemic sclerosis. <i>Journal of Dermatology</i> , 0, , .	0.6	3
984	Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer. <i>Biomedicines</i> , 2022, 10, 1493.	1.4	14
985	Anifrolumab: An Inhibitor of Type I Interferon for the Treatment of Patients with Systemic Lupus Erythematosus. , 2022, 1, 29.		0
986	Systemic Lupus Erythematosus: New Diagnostic and Therapeutic Approaches. <i>Annual Review of Medicine</i> , 2023, 74, 339-352.	5.0	34
988	Recent advances in immunotherapies for lupus nephritis. <i>Pediatric Nephrology</i> , 2023, 38, 1001-1012.	0.9	5
989	Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target. <i>Journal of Autoimmunity</i> , 2022, 132, 102861.	3.0	23
990	Chilblain lupus with nail involvement: a case report. <i>Revista Colombiana De Reumatología (English)</i> Tj ETQq1 1 0.784314 rgBT /Overl 0,1		
991	Cross-species transcriptome analysis for early detection and specific therapeutic targeting of human lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1409-1419.	0.5	9
992	Severe lupus nephritis in the present days. , 0, 2, .		1
993	B cell-targeted therapies in systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2022, 132, 102873.	3.0	12
994	Rituximab as maintenance therapy following remission induction in relapsing or refractory systemic lupus erythematosus. <i>Rheumatology</i> , 2023, 62, 1145-1152.	0.9	3
995	What is new in the treatment of Systemic Lupus Erythematosus?. <i>Vnitřni Lekarství</i> , 2022, 68, 273-278.	0.1	0
996	Extrapolation of Adult Efficacy Data to Pediatric Systemic Lupus Erythematosus: Evaluating Similarities in Exposure-Response. <i>Journal of Clinical Pharmacology</i> , 2023, 63, 105-118.	1.0	4
997	Systemic lupus erythematosus: history and modernity. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022, 60, 397-412.	0.2	11
998	Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature. <i>Autoimmunity Reviews</i> , 2022, 21, 103188.	2.5	9

#	ARTICLE	IF	CITATIONS
999	Why do some patients with systemic lupus erythematosus fail to respond to B-cell depletion using rituximab?. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 262-266.	0.4	13
1000	Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences. <i>Indian Journal of Medical Research</i> , 2022, 155, 335.	0.4	7
1001	B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	13
1002	Egyptian evidence-based consensus on clinical practice recommendations for the management of lupus nephritis. <i>Egyptian Rheumatology and Rehabilitation</i> , 2022, 49, .	0.2	0
1003	An update on the management of refractory cutaneous lupus erythematosus. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
1004	Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
1005	Editorial: Advance in B-cell therapies for the treatment of rheumatic and musculoskeletal diseases. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
1006	Targeted Therapies for Systemic Lupus Erythematosus (SLE): A Critical Appraisal. , 0, , .		0
1007	Medications impact different aspects of the quality of life of patients with systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2023, 26, 99-107.	0.9	3
1008	Successful Generation of CD19 Chimeric Antigen Receptor T Cells from Patients with Advanced Systemic Lupus Erythematosus. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 27-33.	0.6	10
1010	Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial. <i>Trials</i> , 2022, 23, .	0.7	8
1011	Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2022, 18, 683-693.	3.5	18
1012	Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1013	Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase ^{II} , Randomized, ^{Double-blind} , ^{Placebo-controlled} Trial. <i>Arthritis and Rheumatology</i> , 2023, 75, 242-252.	2.9	51
1014	Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus. <i>Rheumatology</i> , 2023, 62, 2601-2610.	0.9	4
1015	B cell depletion and inhibition in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2023, 19, 55-70.	1.3	3
1016	Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2023, 94, 1-9.	0.9	9
1017	Gene Expression and Autoantibody Analysis Revealing Distinct ^{Ancestry-specific} Profiles Associated With Response to Rituximab in Refractory Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2023, 75, 697-710.	2.9	7

#	ARTICLE	IF	CITATIONS
1018	Unraveling the Link between Interferon- λ and Systemic Lupus Erythematosus: From the Molecular Mechanisms to Target Therapies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15998.	1.8	4
1019	Editorial: Advances in systemic lupus erythematosus: The promises and pitfalls of personalized medicine and patient stratification. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
1020	Efficacy and Safety of Rituximab Therapy for Lupus Nephritis Among SLE Female Patients; a Retrospective Hospital-Based Study. <i>Open Access Rheumatology: Research and Reviews</i> , 0, Volume 14, 301-308.	0.8	0
1021	Lupus Nephritis: Current Perspectives and Moving Forward. <i>Journal of Inflammation Research</i> , 0, Volume 15, 6533-6552.	1.6	5
1022	Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin. <i>American Journal of Clinical Dermatology</i> , 0, , .	3.3	4
1023	Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study. <i>British Journal of Dermatology</i> , 2023, 188, 499-505.	1.4	6
1024	New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review. <i>Joint Bone Spine</i> , 2023, 90, 105523.	0.8	18
1025	Genetics of SLE: does this explain susceptibility and severity across racial groups?. <i>Rheumatology</i> , 2023, 62, i15-i21.	0.9	3
1026	Urine biomarker score captures response to induction therapy with lupus nephritis. <i>Pediatric Nephrology</i> , 0, , .	0.9	2
1027	Povetacept, an Enhanced Dual APRIL / BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2023, 75, 1187-1202.	2.9	4
1028	The full range of ophthalmological clinical manifestations in systemic lupus erythematosus. <i>Frontiers in Ophthalmology</i> , 0, 2, .	0.2	0
1029	Rheumatic diseases: From bench to bedside. , 2023, , 27-46.		0
1031	Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6578.	1.8	8
1032	Autologous CD19-Targeted Chimeric Antigen Receptor (CAR)T-Cells as the Future of Systemic Lupus Erythematosus Treatment. <i>Current Rheumatology Reviews</i> , 2023, 19, 260-269.	0.4	4
1033	NLRP12 is an innate immune checkpoint for repressing IFN signatures and attenuating lupus nephritis progression. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	7
1034	Intérêt du dosage des anticorps anti-médicaments dans les rhumatismes inflammatoires. , 2022, , 179-189.		0
1035	B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	9
1036	Treatment of lupus nephritis: consensus, evidence and perspectives. <i>Nature Reviews Rheumatology</i> , 2023, 19, 227-238.	3.5	17

#	ARTICLE	IF	CITATIONS
1037	Therapeutic potential of the current options in treating systemic lupus erythematosus: Challenges and prospective. , 2023, , 333-348.		0
1038	The pathology and potential clinical applicability of interfering T cells in systemic lupus erythematosus. , 2023, , 349-372.		0
1039	Challenges in systemic lupus erythematosus: From bench to bedside. , 2023, , 293-331.		1
1040	Similarity and difference between systemic lupus erythematosus and NZB/W F1 mice by multi-omics analysis. <i>Modern Rheumatology</i> , 2024, 34, 359-368.	0.9	0
1041	Dilemma of immunosuppression and infection risk in systemic lupus erythematosus. <i>Rheumatology</i> , 2023, 62, i22-i29.	0.9	9
1042	Lupus Nephritis. , 2023, , 737-763.		0
1043	Precision medicine in systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2023, 19, 331-342.	3.5	12
1045	Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren's syndrome: evidence- and practice-based guidance. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	8
1051	Current treatment of systemic lupus erythematosus: a clinician's perspective. <i>Rheumatology International</i> , 2023, 43, 1395-1407.	1.5	6
1074	B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis. , 2024, , 299-312.		0
1096	Safety and efficacy of biologics in childhood systemic lupus erythematosus: a critical systematic review. <i>Clinical Rheumatology</i> , 2024, 43, 863-877.	1.0	0
1105	Homeostatic Versus Pathogenic Autoantibodies: Origin, Structure and Effector Functions. , 2024, , 387-412.		0